The board meeting was held in-person and via Zoom and was live streamed.

**Board Members Present:** Vice President Dan Somsen, Ashley Hansen, Cheri Kraemer, and Lenny Petrik. President Tom Nelson was excused.

**Board Staff Present:** Executive Director Kari Shanard-Koenders; PDMP Director Melissa DeNoon, Inspectors Tyler Laetsch, Paula Stotz, and Carol Smith; and Secretary Beth Windschitl.

**Attendees (in-person and via Zoom):**

Madalyne Schuldt, Jessica Strobel, Melissa Gorecki, Lauren Paul, Lorri Walmsley, Jessica Adams, Dan Hansen, Deeb Eid, Kendra Croker, Christopher Le, Becca Mitchell, Andy Tonnesen, Lori Ollerich, Maimuna Bruce, Mark Scott, Amanda Bacon, Justin Manning, Jim Mennen, Charles, Hudek, Sean Grosklags, Amanda Kuhn, Matt Toennies, Rachel Elsey, Robin Lockhorst, Morgan Sandersfeld, Jeff DeRouchey, Tom Johnson, Dana Darger, and Bill Ladwig.

### A. Call to Order, Mission, Roll Call, and Introductions – Vice President Dan Somsen

Meeting was called to order at 8:04 a.m. by Dan Somsen who read the Board mission statement. Introductions were completed. A voice roll call was taken and a quorum present (four board members).

### B. Public Comment

Vice President Somsen opened the floor for public comment. Hearing no comments, he moved to the Consent Agenda.

### C. Consent Agenda

The consent agenda was reviewed. Lenny Petrik made a motion to remove item #2 (April 8, 2021 Board Meeting minutes) from the agenda. Cheri Kraemer seconded; motion passed. Ashley Hansen made a motion to approve the amended consent agenda; motion was seconded by Cheri Kraemer. A roll call vote was taken, and motion passed (4-0).

### D. Staff Reports

1. **Staff Reports – Kari Shanard-Koenders, R.Ph., M.S.J., Executive Director**

   - COVID information on the SD BOP website has been updated
   - We are in process of updating the board website as we have outdated items on it
   - The Executive Order extending the statutory and regulatory suspensions of Board laws and rules expires on June 30
   - The PREP Act provisions may be viable until year end; Board needs to be thinking about next steps. Should we be making the PREP Act provisions permanent next as several entities are now using technicians to immunize.
• SAMHSA and DEA have changed the provisions for the Data Waiver for those providing MAT treatment to 30 patients or fewer
• DEA agents are now in Omaha and Sioux Falls - the board is no longer serviced by the Des Moines branch – DEA has expressed interest in a more robust pharmacy inspection program

2. Inspector Reports

After reviewing inspector reports, Dan Somsen observed that a lot of time is being expended on attending weekly COVID webinars/calls. Kari Shanard-Koenders indicated over time webinars/calls have decreased in both length and number. This trend should continue going forward.

a. Tyler Laetsch
   Reported the following observations/occurrences:
   • Chain pharmacies did not have DEA collector certificate displayed
   • Cases where control substance (CS) inventories were completed on different days; all CS audits must be done on the same
   • Had multiple occurrences of fraudulent scripts
   • Viewed an NAPB VAWD inspection conducted in Sioux Falls
   • Identified multiple cases inventory losses
   • Remember to look for outdated product especially in compounding areas and OTC
   • Completed the first inspection of the new Sioux Empire Triage Center; a unique service delivery model that bring servicing partners together

b. Paula Stotz, Inspector
   Reported the following observations/occurrences:
   • Two LTC pharmacies did not include controlled substances (CS) in the E-kit on their inventory
   • One pharmacy conducted the biennial inventory audit throughout the day vs. opening or closing
   • Four pharmacies did not include filled CS in the Will Call area in the biennial inventory
   • One pharmacy finalized the CSOS orders weekly on the wholesaler website rather than on the day of receipt
   • One pharmacy stopped finalizing CSOS orders several months ago
   • Two pharmacies did not attach the DEA 222 form to the corresponding invoice
   • Two Med Drop boxes were not properly installed; three boxes had none of the required DEA paperwork logs
   • Four pharmacies posted primary verification documents rather the actual a pharmacist license or technician registration
   • Visited CVS in Target Rapid City to view their new Virtual Verification process

c. Carol Smith, Inspector
   Reported the following observations/occurrences:
   • Two pharmacies missing temperature logs
   • A telepharmacy completing controlled substance (CS) audits every six weeks rather than the required monthly audits
   • Three pharmacies not consistently doing CS audits; three pharmacies not properly checking their CS invoices
   • Two pharmacies that have not updated their NIOSH list or do not have a specific list for their pharmacy
• Two pharmacies where collector receptacles were not secured to the floor
• Other noncompliance findings
  o No PDMP sign, failure to revoke POA of pharmacist no longer employed, pharmacist failure to print and post her new license, CS count did not match inventory book, outdated stock not removed from inventory
• Fielded medical marijuana questions

3. PDMP Report
Director Melissa DeNoon reported the following program updates:

PDMP
• SD PDMP currently shares information with 36 PDMP programs nationwide
• Through the RxCheck Hub, sharing with NE was recently established
• Statewide Gateway Integration Project participants in production include Avera Health, Sanford Health, Monument Health, SD Health Link, 4 hospitals, 10 clinics, and 76 pharmacies

MedDrop
• Participation in the program continues to grow from 2 receptacle locations in hospitals and pharmacies in 2017 to 84 receptacle locations in 2021
• Pounds returned for destruction have also increased from 35 lbs. in 2017 to 7,302 lbs. in 2020 and a grand total of 17,309 lbs. destroyed since program inception.

Controlled Substances
• In 2018, 2019, and 2020, Hydrocodone and Tramadol consistently held the number 1 and 2 spots for the top ten controlled substances to SD patients. Trending shows stimulants moving up the list.

E. Complaints, Investigations, Disciplinary Actions, Loss/Theft Reports
Reported by Tyler Laetsch, Paula Stotz, and Carol Smith.

1. DEA Form 106—Walgreens Spearfish
2. DEA Form 106 – Costco Sioux Falls
3. DEA Form 106 - Medvantx Sioux Falls
4. DEA Form 106—Safeway Mount Rushmore Rd, Rapid City
5. DEA Form 106—Safeway Mountain View Rd, Rapid City
6. DEA Form 106—Hyvee Yankton
7. DEA Form 106—CVS Rapid City
8. Complaint #2021-0003
9. DEA Form 106—Dakota Country Pharmacy, Phillip
10. DEA Form 106—Anda loss in transit
11. DEA Form 106—Wal-Mart, Watertown
12. DEA Form 106—Brother’s LTC, Brookings

F. SD Pharmacists Association – Amanda Bacon, SDPhA; Dana Darger, R.Ph., SDPHA President

1. Activity Report

SDPhA Director Amanda Bacon highlighted the following items from the Activity Report handout:
• Spring District meetings and the SDPhA Board retreat were held via Zoom due to COVID-19
• The SDPhA annual meeting will be held in person in Spearfish September 17-18. Online registration will be available once the new SDPhA website launches the week of July 12th. Hotel is Spearfish Holiday Inn.
• IM 26 (medical marijuana) goes into effect July 1st and a decision by the SD Supreme Court on Amendment A (recreational or adult use marijuana) is anxiously awaited. SDPhA has not taken a position on Amendment A choosing instead to continue efforts that position pharmacists as the medication expert and a trusted resource.
• SDPhA continues to monitor developments resulting from the Rutledge ruling and has signed on to participate as Amicus Curiae in PCMA vs. Wilke.
• Director Bacon stressed the need to increase contributions to the Commercial and Legislative Fund and the important role (C&L) funds play in SDPhA’s ability to impact PBM reform and other legislative priorities. Need to engage local and national independent and chain pharmacies, who are impacted by DIR actions, to contribute and contact their legislative representatives.
• To date, SDPhA has enrolled more than 106 participants in Pharmacy Technician University; eight participants enrolled through the high school Dial Up program.
• Student, Benjamin Ostebee, will be completing an APPE rotation in Association Management with SDPhA beginning August 23rd.

2. Financial Report – provided not reviewed

3. Financial Discussion per SDCL 36-11-6

Per the executive director, statute 36-11-6 states the Board of Pharmacy may provide 80% of all fees received for pharmacists’ renewals to the Pharmacists Association annually. The board requested and received no AG opinion regarding 36-11-6 annual funding. Lenny Petrik made a motion to approve the annual funding of SDPhA as required in 36-11-6. Cheri Kraemer seconded the motion. Roll call vote was taken; motion passed (4-0) – Hansen, Kraemer, Petrik, Somsen

G. Other Reports

1. SDSU College of Pharmacy – Dean and Professor Dan Hansen, Pharm.D., College of Pharmacy and Allied Health Professions Department

Dean Hansen shared the following College of Pharmacy and Allied Health Professions updates:
• In May of 2021, four different in-person graduation ceremonies were held on campus; 2020 graduates were also invited back to walk. The P4 oath was given by board member Cheri Kraemer.
• 75 graduates received their Doctorate in Pharmacy.
• 35 of the 2021 PharmD graduates matched with a PGY1 residency program (47% of the class).
• SDSU’s residency match rate of 79.5% exceeded the national match rate of 67%.
• NABP has changed the NAPLEX test scoring to pass/fail only, standardize the test to 150 questions, and allotted six hours for test completion. Going forward, Pharmacy Colleges will only know the percentage of students who passed.
• Fall 2021 students will be on campus for in-person classes.
• The College’s Department of Pharmaceutical Sciences governor’s Research Center proposal was selected as one of the recipients to receive $3.9 million over five years to establish the 3D (Drug, Disease, and Delivery) Research Center.

2. SD Society of Health System Pharmacists – Jeremy Daniel, Pharm.D., Avera (Not in Attendance)

3. SD Association of Pharmacy Technicians – John Thorns, CPhT (Not in Attendance)

Meeting Break at 9:46am and resumed at 10:00am
H. Old Business

1. FDA MOU with States on Compounding – Kari Shanard-Koenders, Executive Director

Ms. Shanard-Koenders reminded attendees that a decision is expected by the October 27th deadline on whether we will sign the Memorandum of Understanding (MOU) addressing the distribution of inordinate amounts of compounded human drug products interstate and the appropriate investigations of complaints relating to compounded human drugs. We have one more Board meeting in September 2021 to further discuss aspects of the MOU. The executive director has contacted the board’s attorney for a determination as to whether or not the board has the authority to sign the MOU.

2. Avera Drug Repository Variance Renewal and Report – Matt Toennis, Pharm D

PGY2 Health System Pharmacy Administration & Leadership resident Amanda Kuhn presented the annual report update for Avera’s Drug Repository Pilot program allowing unused medications to be donated and re-dispensed to patients. Report information analyzed patient program data from drug repository programs (DRPs) and a matched cohort for the period July 1, 2019 to February 28, 2021. Project primary objectives were to track the number of prescriptions filled and average wholesale price of each prescription dispensed through the DRP and to compare the time for patients to receive prescriptions, from time of prescribing to insurance approval. Initially, the pilot program focused on oncology specialty medications due to the expensive nature of the medication and frequent therapy changes. In year two, the goal was to increase the scope of specialty medications across the Avera footprint through education awareness, focusing on disease states of rheumatology, and greater advertisement to patients. Since implementation, over $2.4 million prescription drugs have been donated, and prescriptions have been dispensed to 135 patients, totaling over $1.3 million based on average wholesale pricing with the average cost of each prescription dispensed being $10,000. The program does not accept controlled substances or items requiring refrigeration. The program has a pharmacist that reviews all medication when it comes in to determine viability. Kari Shanard-Koenders indicated there is a legislator who is interested in submitting a legislative bill for next session in conjunction with the Board. Dana Darger, Director of Pharmacy for Monument Health inquired whether the Avera Repository team would be amenable to sharing their pilot project blueprint with other entities, including Monument Health, who would like to establish a similar program.

Ashley Hansen made motion to renew the Avera Drug Repository variance for a period of one year. Lenny Petrik seconded the motion. Motion was amended to include an annual reporting requirement. The floor was opened for comments. Hearing no comments, a roll call vote was taken; motion passed (4-0).

Ashley Hansen made a new motion to allow any other entities that would want to propose to the board a “like pilot project” for a drug repository could obtain executive approval to begin. Motion was seconded by Lenny Petrik. Floor was again opened for comments. Hearing no comments, a roll call vote was taken; motion passed (4-0).


Kari Shanard-Koenders reviewed a proposed minor revision to the June 5, 2020 Board Policy Statement Number 20-06-05. Change will allow the policy to remain in effect until the PREP Act for countermeasures against COVID-19 concludes. A motion was made by Cheri Kraemer to pass Board Policy Statement Number 20-06-05 adjustments as illustrated in handout. Ashley Hansen seconded the motion. Roll call vote was taken, motion passed (4-0).
Tyler Laetsch presented proposed revisions to the December 3, 2010 Board Policy Statement Number 10-12-01 (Guidance for Pharmacy Employees Working at Home). Changes include assigning a policy number, allowing use of a terminal server with two-factor identification, and removal of requiring in-home business telephone line and maintaining a separate designated area in home for work. There was lengthy discussion regarding what constitutes “direct communication” access to a pharmacist and whether pharmacist supervision of the technician and intern electronically should be a separate line item. It was determined that direct communication includes all methods of communication that are part of an entity’s policies and standard operating procedures and pharmacist supervision would be enumerated item number seven.

Cheri Kraemer made a motion to accept the board policy proposal with adjustments as follows:
- #6 to read All pharmacy technicians and interns working remotely must have direct communication access to a pharmacist.
- #7 to read Pharmacist is able to supervise the technician and interns electronically.

Motion seconded by Ashley Hansen. Floor was opened for discussion. Cheri Kraemer made a motion to amend to include the addition of an eighth item requiring technician ratios to be compliant according to the ratios stated in 20:51:29 for all work from home scenarios. Amended motion was seconded by Ashley Hansen. Floor was opened for discussion. Hearing no discussion, a roll call vote was taken, motion passed (4-0).

4. Hy-Vee Telepharmacy – Hartford – Justin Manning, Pharm.D., Jim Mennen, BPharm, MS, MBA; Charles Hudek, R.Ph.

Previously Hy-Vee had submitted an application for a hybrid type telepharmacy in its recently acquired Hartford, SD (previously Medicap) pharmacy and the Board denied the telepharmacy application and approved a full-time pharmacy application. The location currently operates as a traditional pharmacy. Hy-Vee has asked for an application to be approved to operate as a telepharmacy which is why Justin appears before the board. Hy-Vee currently operates six telepharmacy locations – five in Iowa and one in Minnesota all using the Telepharm Software. The new location does a larger pharmacy volume than what would be expected in a telepharmacy model which is why Hy-Vee feels they cannot service their customers appropriately using a full telepharmacy model. Hence the need for the telepharmacy hybrid model. Store hours of operation would be 9am – 7pm with the telepharmacy model being used five days a week Monday through Friday from 9am – 11am when volume is low and a pharmacist onsite 40-45 hours a week during afternoon/evening hours and on Saturday, when volume increases and more customers need counseling. Looking at staffing with two fulltime certified pharmacy technicians with a support person as well. The managing pharmacy will be the Hy-Vee location on Marion Road in Sioux Falls. Script volume at the new location is roughly 1,000 scripts per week with 400-500 filled a week on site and 50% filled through the Hy-Vee Central Fill location with prescriptions delivered two times daily moving to same delivery in the future.

Dan Somsen shared that telepharmacy was designed to be implemented in rural settings and the new Hy-Vee location is less than ten miles from Sioux Falls. Justin Manning stated if the location were to close there would be no pharmacy in Hartford to service customers. The Medicap location was a community pharmacy operating during the same hours. Hy-Vee proposes to process the same prescription volume and accomplish it by using a hybrid telepharmacy model. Hy-Vee feels, from a staffing perspective, they cannot be successful at the location using a traditional pharmacy model. Ashley Hansen expressed concern regarding achieving profit sustainability by decreasing pharmacist employment. Hy-Vee is required to maintain the same technician ratios as a traditional pharmacy, their techs use I-Pads connected directly to a pharmacist when talking with customers, the hours when a pharmacist is onsite are posted, and central data entry is used to help streamline processes. Different aspects of the telepharmacy model continued to be discussed by attendees.
Cheri Kraemer made a motion to reject the application to operate the Hartford Hy-Vee location as a hybrid telepharmacy. Lenny Petrik seconded the motion. Roll call vote was taken; motion passed (4-0).

Acting Chair Somsen turned chair duties to former Board President Petrik and was excused from final agenda items.

I. New Business

1. Walgreens Technician Immunization Variance Request – Lorri Walmsley, R.Ph.

   Lorri Walmsley and Kari Gerdeman presented Walgreen’s Technician-Administered Immunization pilot project expanding the role of technician immunization administration to all ACIP recommended vaccines and to request the board approve a one-year variance to 20:51:28:02.01, 20:51:29:20, 20:51:29:21(6) with a six-month reporting requirement. The program would allow certified immunization trained technicians to perform all ACIP recommended vaccines for patients in all 14 South Dakota locations. Technicians will be supervised by an immunization trained pharmacist and will only participate in the non-clinical portion of vaccine administration. Implementing the program will help increase vaccination rates and improve workflow and environment.

   Discussion occurred and questions were addressed.

   Cheri Kraemer made a motion to approve variance for six months with a six-month reporting requirement. Motion was amended to include specific reporting requirements - ADR data, number of adverse events and customer refusals. Amended motion was seconded by Ms. Hansen. Roll call vote was taken, motion passed (3-0) – Hansen, Kraemer, and Petrik. Somsen excused.

2. Avera Hospital at Home, Glenn Voss, Pharm.D.

   Per Glenn Voss, as a recap, in November of 2020, CMS allowed for the development of a waiver for health care systems to move to models that included payment for CMS Medicare patient populations in a hospital or home environment so Avera has gone through the waiver process and been approved by CMS. Mr. Voss contacted the board to inform them that Avera had obtained a waiver and had begun implementation. The board had two very specific questions. One was the social inclusion / exclusion components that would be present in the policies and activities within the Avera Hospital at Home program and the clinical inclusion / exclusion components for that same program (handout). Avera has completed their due diligence to identify where their opportunities for success and failure lie. There are controlled medications that will be distributed to the home environment from a McKennan distribution methodology. Avera has reached out to their DEA representative for input/direction regarding controlled medications. Controls in the home would be stored in tamper proof lockbox container. A lockbox container could be stored in a refrigerator if medication requires. Medications will be dispensed as if they were completely labeled as a home medication prescription but product in the home remains under ownership by Avera McKennan until consumed by the patient. Day supply could be up to 30-hour supply depending on patient initial admission into the process but in general on a continual basis it would be on a 24-hour. Hospital employees go into the home. Patients meet hospitalization criteria and have all access to activities one would receive in a hospital. Program start date August 1, 2021. Presentation was informational; no variance requested.

3. CVS New Virtual Verification Process – Lauren Paul, Pharm.D., MS

   Lauren Paul, Senior Director, Pharmacy Regulatory Affairs, presented information on the New Virtual Verification Process being used by CVS. This is a process which uses a photographic image for medication fulfillment and verification instead of the manual handling of product. The presentation showed the virtual verification process and how it simplifies/expedites the process to improve patient care. The steps of the virtual
verification process can be reviewed in the power point. A question was raised regarding the cleaning protocol when a tray is used for a NIOSH drug. Ms. Paul indicated she would investigate and follow-up with the board. On 6/29/21, Ms. Paul informed the board that CVS is in the process of providing all pharmacies a second tray that would be used only for NIOSH medications. Pharmacies across the country should have a second tray in place by the end of August.

4. Amicus – GMP Consultants – Becca Mitchell, Pharm.D.

Becca Mitchell, Amicus Director of Quality and Regulatory, requested board approval of Amicus as a qualified contractor to perform inspections of 503B outsourcing facilities. Amicus is an independently owned, private company with no interest in any wholesale or 503B companies. They offer full-service consulting, perform compliance audits, assist with compliance remediation, and provide validation services to FDA-registered entities across the country. Currently, 503B entities seeking licensure in South Dakota are required to provide an FDA inspection as part of their Wholesale and Drug Distributor application.

Cheri Kraemer made a motion to approve Amicus as qualified 503B inspection provider in lieu of an FDA inspection for the purpose of meeting South Dakota licensure requirements. Ashley Hansen seconded the motion. Roll call vote was taken, motion passed (3-0) Hansen, Kraemer, and Petrik. Somsen was excused.

5. Spring Meds – Mark Scott

Briefly in 2020, Spring Meds operated a retail pharmacy in South Dakota which has since closed. Spring Meds Inc. also operates an online (Springmeds.com) business for prescription medication and over-the-counter product purchases. All products are generic, obtained from VAWD approved wholesalers in the U.S., cash only purchases and are currently filled by pharmacies in Kentucky and Utah. In addition to these servicing sites, Springmeds.com plans on opening a Sioux Falls site with the goal of fulfilling all Springmed.com orders in Sioux Falls. No action required. Board will review application when it arrives.

J. Other Business

1. Recent Meeting News
   a. 117th NABP Annual Meeting – Ashley Hansen, Pharm.D.

Ashley attended the virtual NABP Annual meeting where they discussed and approved six resolutions. She provided a summary of topics discussed:

- Emergency provisions in the Prep Act and what to do going forward
- Encouraged boards to prepare for future pandemic and natural disaster responses
- Monitoring the issue of importation of drugs from Canada
- Pharmacy workplace safety
- Promotion of “just culture” regarding medication safety

2. Future Board Meeting Dates – all held in Sioux Falls Board Room unless otherwise noted
   a. September 16, 2021, 1pm – 5pm MDT in coordination with 135th SDPHA Annual Meeting in Spearfish
   c. December 10, 2021, 9am – 1pm CST
   d. April 7, 2022, 1pm – 5pm MDT at The Lodge at Deadwood in coordination with SDSHP 46th Annual Conf
   e. June 24, 2022, 8am – 12 noon

3. Upcoming Meetings
   a. NABP/AACP 84th Annual District V Meeting, August 6, 2021 Virtual Meeting
b. 135th SDPHA Annual Meeting, September 17-18, 2021, Spearfish

c. SDSHP 46th Annual Conference, April 8-9, 2022, Deadwood

d. 118th NAPB Annual Meeting – May 19-21, 2022, Sheraton Wild Horse Pass, Phoenix

e. NABP/AACP 85th Annual District V Meeting, August 3-5, 2022, Custer State Park

K. Adjourn

Cheri Kraemer made a motion to adjourn; motion seconded by Ashley Hansen. Meeting adjourned at 12:17 pm.
PHARMACISTS

2055 Current Total               6 New Licensees for period

<table>
<thead>
<tr>
<th>License#</th>
<th>Last Name</th>
<th>First Name</th>
<th>City</th>
<th>State</th>
</tr>
</thead>
<tbody>
<tr>
<td>R-6837</td>
<td>Nicoski</td>
<td>Randy</td>
<td>Milwaukie</td>
<td>OR</td>
</tr>
<tr>
<td>R-6836</td>
<td>Harmon</td>
<td>Paige</td>
<td>Lombard</td>
<td>IL</td>
</tr>
<tr>
<td>R-6835</td>
<td>Harnois</td>
<td>James</td>
<td>Lockport</td>
<td>IL</td>
</tr>
<tr>
<td>R-6833</td>
<td>Pierson</td>
<td>Max</td>
<td>Worthington</td>
<td>MN</td>
</tr>
<tr>
<td>R-6834</td>
<td>Patel</td>
<td>Ami</td>
<td>Cedar Grove</td>
<td>NJ</td>
</tr>
<tr>
<td>R-6832</td>
<td>Salke</td>
<td>Brandon</td>
<td>Saint Charles</td>
<td>MO</td>
</tr>
</tbody>
</table>

FULL-TIME PHARMACY PERMITS

235 Current Total               3 New FT Permits for period

<table>
<thead>
<tr>
<th>License#</th>
<th>Business</th>
<th>City</th>
<th>State</th>
</tr>
</thead>
<tbody>
<tr>
<td>100-2073</td>
<td>Brown Pharmacy LLC</td>
<td>Watertown</td>
<td>SD</td>
</tr>
<tr>
<td>100-2072</td>
<td>Vytal Pharmacy</td>
<td>Sioux Falls</td>
<td>SD</td>
</tr>
<tr>
<td>100-2071</td>
<td>Hy-Vee, Inc.</td>
<td>Hartford</td>
<td>SD</td>
</tr>
</tbody>
</table>

PART-TIME PHARMACY PERMITS

68 Current Total               1 New PT Permits for period

<table>
<thead>
<tr>
<th>License#</th>
<th>Business</th>
<th>City</th>
<th>State</th>
</tr>
</thead>
<tbody>
<tr>
<td>200-1737</td>
<td>Sioux Empire Triage Center</td>
<td>Sioux Falls</td>
<td>SD</td>
</tr>
</tbody>
</table>

PHARMACY INTERNS

308 Current Total               8 New Registrations for period

TECHNICIAN REGISTRATIONS

1493 Current Total               71 New Registrations for period

NON-RESIDENT PERMITS

839 Current Total               23 New NR Permits for period

WHOLESALE PERMITS

1264 Current Total               51 New WH Permits for period
<table>
<thead>
<tr>
<th>Activity Reports</th>
<th>New</th>
<th>Renewal</th>
<th>May 2021</th>
<th>May 2020</th>
<th>YTD This Year</th>
<th>YTD Last Year</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pharmacy Permits</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Full Time (SD)</td>
<td>2</td>
<td>117</td>
<td>119</td>
<td>99</td>
<td>130</td>
<td>105</td>
</tr>
<tr>
<td>Part Time (SD)</td>
<td>0</td>
<td>22</td>
<td>22</td>
<td>31</td>
<td>27</td>
<td>42</td>
</tr>
<tr>
<td>Non-Resident</td>
<td>5</td>
<td>380</td>
<td>385</td>
<td>261</td>
<td>587</td>
<td>429</td>
</tr>
<tr>
<td><strong>Pharmacist Licenses</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South Dakota</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1305</td>
<td>1279</td>
</tr>
<tr>
<td>Non-Resident</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>763</td>
<td>760</td>
</tr>
<tr>
<td><strong>Technician Registration</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>32</td>
<td>2</td>
<td>34</td>
<td>20</td>
<td>1495</td>
<td>1703</td>
</tr>
<tr>
<td><strong>Pharmacy Interns</strong></td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>346</td>
<td>333</td>
</tr>
<tr>
<td><strong>Wholesale Permits</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>South Dakota</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>48</td>
<td>62</td>
</tr>
<tr>
<td>Non-Resident</td>
<td>22</td>
<td>2</td>
<td>24</td>
<td>11</td>
<td>1271</td>
<td>1242</td>
</tr>
<tr>
<td><strong>Inspections</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmacy Inspections</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>26</td>
<td>24</td>
</tr>
<tr>
<td>Wholesale Inspections</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Other Pharmacy Visits/Meetings</td>
<td>37</td>
<td>65</td>
<td>680</td>
<td>451</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Controlled Drug Destruction</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PDMP Visits</td>
<td>17</td>
<td>13</td>
<td>177</td>
<td>161</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Approvals, Variances, and Pharmacy changes for June 25, 2021 Board Meeting

Approvals
1. Remote Pick Up site in Selby for Turner Drug in Bowdle

Variances/Waivers
1. Renewal of Automated Ekit Variance for PharMerica RxNow Machines in Avantara Mountain View; Avantara North; Avanatara Arrowhead; Fountain Springs; all of Rapid City and Avantara Pierre.

New Pharmacies/Closed Pharmacies and New/Closed Wholesale Distributors
1. CHOW SD Full-Time Pharmacy, Hy-Vee Pharmacy #3633, Hartford, #100-2071
2. New SD Full-Time Pharmacy, Vytal Pharmacy, Sioux Falls, #100-2072
3. New SD Full-Time Pharmacy, Brown Pharmacy LLC dba Downtown Drug, Watertown, #100-2073
4. CHOW SD Full-Time Pharmacy, Avera St. Luke’s dba Avera State Street Pharmacy, Aberdeen, #100-2074
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Wholesale</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>35</td>
<td>0</td>
<td>0</td>
<td>35</td>
</tr>
<tr>
<td>FT Pharmacy</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PT Pharmacy</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Nonresident</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Initial Certification</td>
<td>105</td>
<td>0</td>
<td>35</td>
<td>70</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>210</td>
</tr>
<tr>
<td>RPh Renewal / New</td>
<td>625</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>750</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1,375</td>
</tr>
<tr>
<td>Interns</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Reciprocity</td>
<td>450</td>
<td>0</td>
<td>150</td>
<td>300</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>150</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1,050</td>
</tr>
<tr>
<td>Technicians</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>1,300</td>
<td>0</td>
<td>600</td>
<td>1,600</td>
<td>-300</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>3,200</td>
</tr>
<tr>
<td>Other - Electronic Fees</td>
<td>13,375</td>
<td>92,680</td>
<td>173,790</td>
<td>45,475</td>
<td>142,040</td>
<td>143,245</td>
<td>21,535</td>
<td>8,565</td>
<td>8,165</td>
<td>8,565</td>
<td>21,535</td>
<td>0</td>
<td>678,970</td>
</tr>
<tr>
<td>Late Fee Penalties</td>
<td>25</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>25</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>50</td>
</tr>
<tr>
<td>Recovery Legal Fees</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Fines, Forfeits &amp; Penalties</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Interest Revenue</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Sub-Total</td>
<td>15,880</td>
<td>92,680</td>
<td>174,575</td>
<td>47,445</td>
<td>141,740</td>
<td>143,245</td>
<td>21,535</td>
<td>8,565</td>
<td>9,125</td>
<td>8,565</td>
<td>21,535</td>
<td>0</td>
<td>684,890</td>
</tr>
<tr>
<td>Federal Grant Program GY7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.00</td>
</tr>
<tr>
<td>CASH CENTER BALANCE</td>
<td>$636,522.72</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Remaining Authority by Object/Subobject**

**Expenditures current through 05/29/2021 03:50:49 PM**

**HEALTH -- Summary**

**FY 2021** Version -- AS -- Budgeted and informational

FY Remaining: 9.0%

<table>
<thead>
<tr>
<th>Subobject</th>
<th>Board of Pharmacy - Info</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EMPLOYEE SALARIES</strong></td>
<td></td>
</tr>
<tr>
<td>5101010</td>
<td>F-t Emp Sal &amp; Wages</td>
</tr>
<tr>
<td>5101020</td>
<td>P-t/temp Emp Sal &amp; Wages</td>
</tr>
<tr>
<td>5101030</td>
<td>Board &amp; Comm Mbrs Fees</td>
</tr>
<tr>
<td>Subtotal</td>
<td></td>
</tr>
</tbody>
</table>

| Subtotal | 693,037 | 452,656 | 0 | 0 | 240,381 | 34.7 |

| **EMPLOYEE BENEFITS** | |
| 5102010  | Oasi-employer's Share |
| 5102020  | Retirement-er Share |
| 5102060  | Health Insurance-er Share |
| 5102080  | Worker's Compensation |
| 5102090  | Unemployment Compensation |
| Subtotal  | |

| Subtotal | 155,696 | 128,838 | 0 | 0 | 26,858 | 17.3 |

| **51 Personal Services** | |
| Subtotal | 848,733 | 581,494 | 0 | 0 | 267,239 | 31.5 |

| **TRAVEL** | |
| 5203010 | Auto-state Owned-in State |
| 5203020 | Auto Priv (in-st.) L/rte |
| 5203030 | Auto-priv (in-st.) H/rte |
| 5203040 | Air-state Owned-in State |
| 5203100 | Lodging/in-state |
| 5203140 | Meals/taxable/in-state |
| 5203150 | Non-taxable Meals/in-st |
| 5203220 | Auto-priv.(out-state) L/r |
| 5203230 | Auto-priv.(out-state) H/r |
| 5203260 | Air-comm-out-of-state |
| 5203280 | Other-public-out-of-state |
| 5203300 | Lodging/out-state |
| 5203320 | Incidental-out-of-state |
| 5203350 | Non-taxable Meals/out-st |
| Subtotal | |

| Subtotal | 49,339 | 2,811 | 0 | 0 | 46,528 | 94.3 |

| **CONTRACTUAL SERVICES** | |
| 5204010 | Subscriptions |
| 5204020 | Dues & Membership Fees |
| 5204050 | Computer Consultant |
| 5204080 | Legal Consultant |
| **Subtotal** | |

<p>| <strong>Subtotal</strong> | 250 | 0 | 0 | 0 | 250 | 100.0 |
| <strong>Subtotal</strong> | 500 | 405 | 0 | 0 | 95 | 19.0 |
| <strong>Subtotal</strong> | 258,067 | 500,210 | 1,020 | 0 | -243,163 | 0.0 |
| <strong>Subtotal</strong> | 4,278 | 0 | 0 | 0 | 4,278 | 100.0 |</p>
<table>
<thead>
<tr>
<th>Subobject</th>
<th>Operating</th>
<th>Expenditures</th>
<th>Encumbrances</th>
<th>Commitments</th>
<th>Remaining</th>
<th>PCT AVL</th>
</tr>
</thead>
<tbody>
<tr>
<td>5204140</td>
<td>20,000</td>
<td>18,000</td>
<td>0</td>
<td>0</td>
<td>2,000</td>
<td>10.0</td>
</tr>
<tr>
<td>5204160</td>
<td>4,000</td>
<td>909</td>
<td>0</td>
<td>0</td>
<td>3,091</td>
<td>77.3</td>
</tr>
<tr>
<td>5204180</td>
<td>11,309</td>
<td>22,077</td>
<td>0</td>
<td>0</td>
<td>-10,768</td>
<td>0.0</td>
</tr>
<tr>
<td>5204181</td>
<td>3,919</td>
<td>192</td>
<td>0</td>
<td>0</td>
<td>3,727</td>
<td>95.1</td>
</tr>
<tr>
<td>5204200</td>
<td>6,270</td>
<td>6,385</td>
<td>0</td>
<td>0</td>
<td>-115</td>
<td>0.0</td>
</tr>
<tr>
<td>5204202</td>
<td>103</td>
<td>34</td>
<td>0</td>
<td>0</td>
<td>69</td>
<td>67.0</td>
</tr>
<tr>
<td>5204203</td>
<td>103</td>
<td>52</td>
<td>0</td>
<td>0</td>
<td>51</td>
<td>49.5</td>
</tr>
<tr>
<td>5204204</td>
<td>418</td>
<td>393</td>
<td>0</td>
<td>0</td>
<td>25</td>
<td>6.0</td>
</tr>
<tr>
<td>5204207</td>
<td>3,638</td>
<td>4,299</td>
<td>0</td>
<td>0</td>
<td>-661</td>
<td>0.0</td>
</tr>
<tr>
<td>5204220</td>
<td>600</td>
<td>3,452</td>
<td>0</td>
<td>0</td>
<td>-2,852</td>
<td>0.0</td>
</tr>
<tr>
<td>5204320</td>
<td>1,000</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1,000</td>
<td>100.0</td>
</tr>
<tr>
<td>5204360</td>
<td>1,000</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1,000</td>
<td>100.0</td>
</tr>
<tr>
<td>5204430</td>
<td>1,000</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>1,000</td>
<td>100.0</td>
</tr>
<tr>
<td>5204460</td>
<td>1,100</td>
<td>1,100</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>5204490</td>
<td>39,277</td>
<td>38,978</td>
<td>0</td>
<td>0</td>
<td>299</td>
<td>0.8</td>
</tr>
<tr>
<td>5204510</td>
<td>250</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>250</td>
<td>100.0</td>
</tr>
<tr>
<td>5204530</td>
<td>5,200</td>
<td>3,838</td>
<td>0</td>
<td>0</td>
<td>1,362</td>
<td>26.2</td>
</tr>
<tr>
<td>5204550</td>
<td>50</td>
<td>57</td>
<td>0</td>
<td>0</td>
<td>-7</td>
<td>0.0</td>
</tr>
<tr>
<td>5204590</td>
<td>1,450</td>
<td>579</td>
<td>0</td>
<td>0</td>
<td>871</td>
<td>60.1</td>
</tr>
<tr>
<td>5204620</td>
<td>196,708</td>
<td>202,400</td>
<td>0</td>
<td>0</td>
<td>-5,692</td>
<td>0.0</td>
</tr>
<tr>
<td>5204960</td>
<td>407,028</td>
<td>64,307</td>
<td>0</td>
<td>0</td>
<td>342,721</td>
<td>84.2</td>
</tr>
</tbody>
</table>

**Subtotal**

|          | 967,518  | 867,667  | 1,020  | 0     | 98,831  | 10.2   |

**SUPPLIES & MATERIALS**

<table>
<thead>
<tr>
<th>Subobject</th>
<th>Operating</th>
<th>Expenditures</th>
<th>Encumbrances</th>
<th>Commitments</th>
<th>Remaining</th>
<th>PCT AVL</th>
</tr>
</thead>
<tbody>
<tr>
<td>5205020   Office Supplies</td>
<td>2,300</td>
<td>3,481</td>
<td>0</td>
<td>0</td>
<td>-1,181</td>
<td>0.0</td>
</tr>
<tr>
<td>5205040   Educ &amp; Instruc Supplies</td>
<td>300</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>300</td>
<td>100.0</td>
</tr>
<tr>
<td>5205212   Printing-state</td>
<td>1,100</td>
<td>772</td>
<td>0</td>
<td>0</td>
<td>328</td>
<td>29.8</td>
</tr>
<tr>
<td>5205310   Printing-commercial</td>
<td>400</td>
<td>56</td>
<td>0</td>
<td>0</td>
<td>344</td>
<td>86.0</td>
</tr>
<tr>
<td>5205320   Supp. Public &amp; Ref Mat</td>
<td>50</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>50</td>
<td>100.0</td>
</tr>
<tr>
<td>5205350   Postage</td>
<td>4,900</td>
<td>1,003</td>
<td>0</td>
<td>0</td>
<td>3,897</td>
<td>79.5</td>
</tr>
</tbody>
</table>

**Subtotal**

|          | 9,050     | 6,102        | 0            | 0           | 2,948     | 32.6    |

**CAPITAL OUTLAY**

<table>
<thead>
<tr>
<th>Subobject</th>
<th>Operating</th>
<th>Expenditures</th>
<th>Encumbrances</th>
<th>Commitments</th>
<th>Remaining</th>
<th>PCT AVL</th>
</tr>
</thead>
<tbody>
<tr>
<td>5207901   Computer Hardware</td>
<td>5,764</td>
<td>3,522</td>
<td>0</td>
<td>0</td>
<td>2,242</td>
<td>38.9</td>
</tr>
<tr>
<td>5207960   Computer Software</td>
<td>30,000</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>30,000</td>
<td>100.0</td>
</tr>
<tr>
<td>5207961   Computer Software</td>
<td>0</td>
<td>295</td>
<td>0</td>
<td>0</td>
<td>-295</td>
<td>0.0</td>
</tr>
</tbody>
</table>

**Subtotal**

<p>|          | 35,764    | 3,817        | 0            | 0           | 31,947    | 89.3    |</p>
<table>
<thead>
<tr>
<th>Subtotal</th>
<th>1,061,671</th>
<th>880,397</th>
<th>1,020</th>
<th>0</th>
<th>180,254</th>
<th>17.0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>1,910,404</td>
<td>1,461,891</td>
<td>1,020</td>
<td>0</td>
<td>447,493</td>
<td>23.4</td>
</tr>
</tbody>
</table>

Remaining Authority by Object/Subobject
Expenditures current through 05/29/2021 03:50:49 PM
HEALTH -- Summary
FY 2021    Version -- AS -- Budgeted and Informational
FY Remaining:  9.0 %
<table>
<thead>
<tr>
<th>Date</th>
<th>Destination</th>
<th>City</th>
<th>Purpose</th>
<th>PDMP/ Narc Destruction, etc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/09/2021</td>
<td>Presentation at SDSHP on BOP Update with Tyler and Melissa</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>04/09/2021</td>
<td>Monthly NABP Ex Off Meeting</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>04/10/2021</td>
<td>Attend SDSHP Meeting and CE</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>04/12/2021</td>
<td>Rural OUD Advisory Committee</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>04/15/2021</td>
<td>What to Expect if DEA comes</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>04/15/2021</td>
<td>Education Committee</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>04/15/2021</td>
<td>DOH Covid Call</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>04/15/2021</td>
<td>COCA Call J&amp;J Vaccine</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>04/19/2021</td>
<td>Presentation at SDSHP on BOP Update with Tyler and Melissa</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>04/20/2021</td>
<td>Joint Press Conference Dr. Clayton and KMR</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>04/22/2021</td>
<td>DOH Covid Call</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>04/27/2021</td>
<td>COCA Call J&amp;J Vaccine Thrombosis</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>04/27/2021</td>
<td>Consumer Protection Funds Meeting</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>04/29/2021</td>
<td>DOH Covid Call</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>04/30/2021</td>
<td>Sarah Jungers Meeting</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>05/03/2021</td>
<td>Surgery Out Three Weeks</td>
<td>Sioux Falls</td>
<td>Surgery</td>
<td></td>
</tr>
<tr>
<td>05/12/2021</td>
<td>NABP Annual Meeting</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>05/13/2021</td>
<td>NABP Annual Meeting</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>05/14/2021</td>
<td>NABP Annual Meeting</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>05/21/2021</td>
<td>NASHP State Webinar</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>05/25/2021</td>
<td>Seton Hall MSJ Graduation</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>05/27/2021</td>
<td>NASCSA Education Committee</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>05/27/2021</td>
<td>DOH Covid Call</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>05/28/2021</td>
<td>The Link Initial Inspection Tyler, Nathan</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>06/02/2021</td>
<td>Security Training</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>06/02/2021</td>
<td>Staff Records Retention Meeting</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>06/02/2021</td>
<td>Tyler, Nathan, and Cardinal Health NUC Tele Disc</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>06/02/2021</td>
<td>Tyler, Nathan, and Amicus Group</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>06/04/2021</td>
<td>Tyler, Nathan, and Avera - Hospital at Home</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>06/05/2021</td>
<td>Completion NABP 2021 Resources and Responsibilities</td>
<td>Sioux Falls</td>
<td>Project</td>
<td></td>
</tr>
<tr>
<td>06/09/2021</td>
<td>Staff Records Retention Meeting</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>06/10/2021</td>
<td>DOH Covid Call</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>06/17/2021</td>
<td>Susan Sporrer, Melissa, Kari Opioid/PDMP Discussion</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>06/24/2021</td>
<td>DOH Covid Call</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>06/25/2021</td>
<td>SD Board of Pharmacy Quarterly Meeting</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>06/25/2021</td>
<td>NABP Monthly EO</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
</tbody>
</table>
### Board of Pharmacy - Inspection Report 2nd Quarter 2021

**Melissa DeNoon**

<table>
<thead>
<tr>
<th>Date</th>
<th>Destination</th>
<th>City</th>
<th>Purpose</th>
<th>PDMP/NARC Destruction etc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>4/9/21</td>
<td>SDSHP</td>
<td>Sioux Falls</td>
<td>Annual Conference</td>
<td>BOP/PDMP Presentation</td>
</tr>
<tr>
<td>4/12/21</td>
<td>Rural OUD Advisory Board</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>4/14/21</td>
<td>NADDI</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>4/14/21</td>
<td>NASCSA</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>4/15/21</td>
<td>DOH</td>
<td>Sioux Falls</td>
<td>Covid Zoom Call</td>
<td></td>
</tr>
<tr>
<td>4/15/21</td>
<td>NASCSA PMP Committee</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>4/21/21</td>
<td>Appriss Health &amp; PDMP Staff</td>
<td>Sioux Falls</td>
<td>Bimonthly CRM &amp; SGI CC</td>
<td></td>
</tr>
<tr>
<td>4/22/21</td>
<td>SDSU COP P2 Law Class</td>
<td>Brookings</td>
<td>Annual PDMP Presentation</td>
<td>PDMP Presentation</td>
</tr>
<tr>
<td>4/23/21</td>
<td>TTAC/NASCSA Veterinary Best Practices Workgroup</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>4/23/21</td>
<td>DOH RFP Review Team</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>4/27/21</td>
<td>USD Sanford School of Medicine QI Boot Camp</td>
<td>Sioux Falls</td>
<td>Zoom Mtg Funding Disc.</td>
<td></td>
</tr>
<tr>
<td>4/29/21</td>
<td>DOH</td>
<td>Sioux Falls</td>
<td>Covid Zoom Call</td>
<td></td>
</tr>
<tr>
<td>4/29/21</td>
<td>NASCSA Executive Committee</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>4/30/21</td>
<td>DOH CDC OD2A Team</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>5/5/21</td>
<td>Appriss Health &amp; PDMP Staff</td>
<td>Sioux Falls</td>
<td>Bimonthly CRM &amp; SGI CC</td>
<td></td>
</tr>
<tr>
<td>5/6/21</td>
<td>DOH</td>
<td>Sioux Falls</td>
<td>Covid Zoom Call</td>
<td></td>
</tr>
<tr>
<td>5/13/21</td>
<td>DOH</td>
<td>Sioux Falls</td>
<td>Covid Zoom Call</td>
<td></td>
</tr>
<tr>
<td>5/13/21</td>
<td>RxCheck Governance Board</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>5/15/21</td>
<td>State of AK Office of Substance Misuse &amp; Addiction Prevention</td>
<td>Sioux Falls</td>
<td>Trilogy MedWaste MedDrop Program Discussion</td>
<td></td>
</tr>
<tr>
<td>5/19/21</td>
<td>Appriss Health &amp; PDMP Staff</td>
<td>Sioux Falls</td>
<td>Bimonthly CRM &amp; SGI CC</td>
<td></td>
</tr>
<tr>
<td>5/20/21</td>
<td>DOH</td>
<td>Sioux Falls</td>
<td>Covid Zoom Call</td>
<td></td>
</tr>
<tr>
<td>5/20/21</td>
<td>NASCSA PMP Committee</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>5/20/21</td>
<td>PMPi Legislative &amp; Policy Subcommittee</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>5/20/21</td>
<td>TTAC PDMP Admin Compliance Group</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>5/21/21</td>
<td>MI PDMP - Haley Winans</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>5/21/21</td>
<td>NASCSA Executive Committee</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>5/24/21</td>
<td>Rural OUD Advisory Board</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>5/25/21</td>
<td>NADDI</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>5/25/21</td>
<td>NASCSA Data Integrity Subcommittee</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>5/25/21</td>
<td>DOH</td>
<td>Sioux Falls</td>
<td>Data Extract Zoom Mting</td>
<td></td>
</tr>
<tr>
<td>5/26/21</td>
<td>TTAC/NASCSA Veterinary Best Practices Workgroup</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>5/27/21</td>
<td>DOH</td>
<td>Sioux Falls</td>
<td>Covid Zoom Call</td>
<td></td>
</tr>
<tr>
<td>5/27/21</td>
<td>TTAC</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>6/1/21</td>
<td>FDA</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>6/2/21</td>
<td>Appriss Health &amp; PDMP Staff</td>
<td>Sioux Falls</td>
<td>Bimonthly CRM &amp; SGI CC</td>
<td></td>
</tr>
<tr>
<td>6/2/21</td>
<td>DOH CDC OD2A Team</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>6/7/21</td>
<td>NASCSA Membership Committee</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>6/10/21</td>
<td>DOH</td>
<td>Sioux Falls</td>
<td>Covid Zoom Call</td>
<td></td>
</tr>
<tr>
<td>6/10/21</td>
<td>RxCheck Governance Board</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>6/11/21</td>
<td>NASCSA Executive Committee</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>6/15/21</td>
<td>NABP 2021 Program Review and Training</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>6/16/21</td>
<td>Appriss Health &amp; PDMP Staff</td>
<td>Sioux Falls</td>
<td>Bimonthly CRM &amp; SGI CC</td>
<td></td>
</tr>
<tr>
<td>6/17/21</td>
<td>NASCSA PMP Committee</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>6/17/21</td>
<td>Opioid/PDMP/HIE Leaders and DOH</td>
<td>Sioux Falls</td>
<td>Programs’ Discussion</td>
<td></td>
</tr>
<tr>
<td>6/21/21</td>
<td>Residents</td>
<td>Sioux Falls</td>
<td>PDMP Presentation</td>
<td>PDMP Presentation</td>
</tr>
<tr>
<td>6/22/21</td>
<td>NASCSA Data Integrity Subcommittee</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>6/24/21</td>
<td>TTAC</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>6/25/21</td>
<td>SD Board of Pharmacy</td>
<td>Sioux Falls</td>
<td>Quarterly Board Meeting</td>
<td></td>
</tr>
<tr>
<td>6/25/21</td>
<td>DOH CDC OD2A Team</td>
<td>Sioux Falls</td>
<td>Zoom Meeting</td>
<td></td>
</tr>
<tr>
<td>Date</td>
<td>Destination</td>
<td>City</td>
<td>Purpose</td>
<td>PDMP/ Narc Destruction etc</td>
</tr>
<tr>
<td>---------</td>
<td>---------------------------</td>
<td>---------------</td>
<td>------------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>4/9/21</td>
<td>SDSHP Presentation</td>
<td>Sioux Falls</td>
<td>Virtual Meeting</td>
<td></td>
</tr>
<tr>
<td>4/12/21</td>
<td>Walgreen’s Kiwanis</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>4/13/21</td>
<td>Siouxland Surgical Center #1</td>
<td>Dakota Dunes</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>4/13/21</td>
<td>Siouxland Surgical Center #2</td>
<td>Dakota Dunes</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>4/14/21</td>
<td>NABP DEA Update Presentation</td>
<td>Sioux Falls</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4/15/21</td>
<td>DOH COVID Update</td>
<td>Sioux Falls</td>
<td>Virtual Meeting</td>
<td></td>
</tr>
<tr>
<td>4/19/21</td>
<td>SDSU P2 Regulatory Talk</td>
<td>Sioux Falls</td>
<td>Virtual Meeting</td>
<td></td>
</tr>
<tr>
<td>4/20/21</td>
<td>Lewis Family Drug</td>
<td>De Smet</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>4/20/21</td>
<td>Avera De Smet Memorial Hospital</td>
<td>De Smet</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>4/22/21</td>
<td>Apria</td>
<td>Sioux Falls</td>
<td>Wholesale Inspection</td>
<td></td>
</tr>
<tr>
<td>4/22/21</td>
<td>DOH COVID Update</td>
<td>Sioux Falls</td>
<td>Virtual Meeting</td>
<td></td>
</tr>
<tr>
<td>4/22/21</td>
<td>Lewis Long Term Care</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>4/26/21</td>
<td>Walmart</td>
<td>Mitchell</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>4/26/21</td>
<td>Animal Health</td>
<td>Mitchell</td>
<td>Wholesale Inspection</td>
<td></td>
</tr>
<tr>
<td>4/27/21</td>
<td>Lewis Family Drug-County Fair</td>
<td>Mitchell</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>4/27/21</td>
<td>Walgreens</td>
<td>Mitchell</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>4/29/21</td>
<td>Davis Pharmacy</td>
<td>Vermillion</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>4/29/21</td>
<td>Sanford Vermillion Hospital</td>
<td>Vermillion</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>5/6/21</td>
<td>DOH COVID Update</td>
<td>Sioux Falls</td>
<td>Virtual Meeting</td>
<td></td>
</tr>
<tr>
<td>5/7/21</td>
<td>Animal Health VAWD Virtual Call</td>
<td>Sioux Falls</td>
<td>Virtual Meeting</td>
<td></td>
</tr>
<tr>
<td>5/11/21</td>
<td>Animal Health VAWD on site</td>
<td>Sioux Falls</td>
<td>VAWD Inspection</td>
<td></td>
</tr>
<tr>
<td>5/12/21</td>
<td>Encompass Health</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>5/13/21</td>
<td>DOH COVID Update</td>
<td>Sioux Falls</td>
<td>Virtual Meeting</td>
<td></td>
</tr>
<tr>
<td>5/13/21</td>
<td>Sanford Oncology Clinic Pharmacy</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/18/21</td>
<td>Walmart Minn. Ave</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/18/21</td>
<td>Hyvee #5</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/19/21</td>
<td>Lewis Family Drug</td>
<td>Wessington Springs</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/19/21</td>
<td>Weskota Memorial Hospital</td>
<td>Wessington Springs</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>5/20/21</td>
<td>Northside</td>
<td>Huron</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/20/21</td>
<td>Coburn’s</td>
<td>Huron</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/26/21</td>
<td>Roger's Pharmacy</td>
<td>Yankton</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/26/21</td>
<td>Yankton Medical Clinic Pharmacy</td>
<td>Yankton</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/27/21</td>
<td>DOH COVID Update</td>
<td>Sioux Falls</td>
<td>Virtual Meeting</td>
<td></td>
</tr>
<tr>
<td>5/28/21</td>
<td>Sioux Empire Triage Center</td>
<td>Sioux Falls</td>
<td>Opening Inspection</td>
<td></td>
</tr>
<tr>
<td>6/1/21</td>
<td>FDA Drug Topics Webinar</td>
<td>Sioux Falls</td>
<td>Virtual Meeting</td>
<td></td>
</tr>
<tr>
<td>6/1/21</td>
<td>AMICUS call</td>
<td>Sioux Falls</td>
<td>Virtual Meeting</td>
<td></td>
</tr>
<tr>
<td>6/2/21</td>
<td>Staff Meeting</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>6/3/21</td>
<td>Cardinal Nuclear Pharmacy Call</td>
<td>Sioux Falls</td>
<td>Virtual Meeting</td>
<td></td>
</tr>
<tr>
<td>6/3/21</td>
<td>Hyvee Louise Ave</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/4/21</td>
<td>Hyvee</td>
<td>Yankton</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/4/21</td>
<td>Walgreens</td>
<td>Yankton</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/7/21</td>
<td>Lincare</td>
<td>North Sioux City</td>
<td>Wholesale Inspection</td>
<td></td>
</tr>
<tr>
<td>6/7/21</td>
<td>Lewis Family Pharmacy</td>
<td>Elk Point</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/9/21</td>
<td>Staff Meeting</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>6/9/21</td>
<td>HyVee W 10th St</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/10/21</td>
<td>Huron Medical Center</td>
<td>Huron</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/10/21</td>
<td>Lewis</td>
<td>Mitchell</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/14/21</td>
<td>Avera LTC</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/14/21</td>
<td>Lifescape</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>6/15/21</td>
<td>NAPB Training</td>
<td>Sioux Falls</td>
<td>Virtual Meeting</td>
<td></td>
</tr>
<tr>
<td>6/16/21</td>
<td>Walmart Louise Ave</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/17/21</td>
<td>Avera Flandreau</td>
<td>Flandreau</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>6/17/21</td>
<td>Lewis Family Pharmacy</td>
<td>Flandreau</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/21/21</td>
<td>Lewis Westgate</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/21/21</td>
<td>Avel eCare</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>6/22/21</td>
<td>Praxair</td>
<td>Sioux Falls</td>
<td>Wholesale Inspection</td>
<td></td>
</tr>
<tr>
<td>6/22/21</td>
<td>Walgreens- Louise Ave</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/23/21</td>
<td>Hyvee Sycamore Ave</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/23/21</td>
<td>Avera Campus Pharmacy</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/25/21</td>
<td>Quarterly Board Meeting</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>Date</td>
<td>Destination</td>
<td>City</td>
<td>Purpose</td>
<td>PDMP/ Narc Destruction etc</td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------------------------------</td>
<td>------------------</td>
<td>----------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>4/14/21</td>
<td>What to Expect When the DEA Visits Your Hospital or Healthcare Facility</td>
<td>Rapid City</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>4/14/21</td>
<td>Plastic Surgery Center of Rapid City</td>
<td>Rapid City</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>4/15/21</td>
<td>HDA 2021 Traceability Reaching 2023</td>
<td>Rapid City</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>4/15/21</td>
<td>DOH COVID-19 Weekly Update</td>
<td>Rapid City</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>4/21/21</td>
<td>DOH Joint Press Conference</td>
<td>Rapid City</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>4/22/21</td>
<td>EPA Hazardous Waste</td>
<td>Rapid City</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>4/22/21</td>
<td>DOH COVID-19 Weekly Update</td>
<td>Rapid City</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>4/28/21</td>
<td>Legal Issues Facing Pharmacy</td>
<td>Rapid City</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>4/29/21</td>
<td>HDA Webinar series</td>
<td>Rapid City</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>4/29/21</td>
<td>DOH COVID-19 Weekly Update</td>
<td>Rapid City</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>4/29/21</td>
<td>Black Hills Surgical Hospital</td>
<td>Rapid City</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>5/4/21</td>
<td>Vilas Pharmacy</td>
<td>Faith</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/4/21</td>
<td>Vilas Pharmacy</td>
<td>Eagle Butte</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/5/21</td>
<td>Smith's Pharmacy</td>
<td>Lemmon</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/12/21</td>
<td>HAD Webinar Series</td>
<td>Rapid City</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>5/13/21</td>
<td>NABP Virtual Convention</td>
<td>Rapid City</td>
<td>Convention</td>
<td></td>
</tr>
<tr>
<td>5/14/21</td>
<td>NABP Virtual Convention</td>
<td>Rapid City</td>
<td>Convention</td>
<td></td>
</tr>
<tr>
<td>5/18/21</td>
<td>White River Community Pharmacy</td>
<td>White River</td>
<td>Telepharmacy Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/18/21</td>
<td>The Winner Pharmacy</td>
<td>Winner</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/19/21</td>
<td>Winner Family Drug</td>
<td>Winner</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/19/21</td>
<td>Winner Regional Healthcare Center</td>
<td>Winner</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/20/21</td>
<td>Burke Community Pharmacy</td>
<td>Burke</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/20/21</td>
<td>Community Memorial Hospital</td>
<td>Burke</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/26/21</td>
<td>Thrifty White Drug</td>
<td>Deadwood</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/26/21</td>
<td>Monument Health Lead Deadwood Hospital</td>
<td>Deadwood</td>
<td>Telepharmacy Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/27/21</td>
<td>DOH COVID-19 Weekly Update</td>
<td>Rapid City</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>6/9/21</td>
<td>Uptown Market - Remote Pick Up Site</td>
<td>Selby</td>
<td>Pick Up Site Visit</td>
<td></td>
</tr>
<tr>
<td>6/9/21</td>
<td>Bowdle Hospital</td>
<td>Bowdle</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/9/21</td>
<td>Turner Drug</td>
<td>Bowdle</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/10/21</td>
<td>Avera Gettysburg Hospital</td>
<td>Gettysburg</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>6/10/21</td>
<td>Vilas Pharmacy</td>
<td>Gettysburg</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/15/21</td>
<td>BHR Managing Conflict</td>
<td>Rapid City</td>
<td>Training</td>
<td></td>
</tr>
<tr>
<td>6/15/21</td>
<td>CVS Pharmacy in Target</td>
<td>Rapid City</td>
<td>Site Visit</td>
<td></td>
</tr>
<tr>
<td>6/16/21</td>
<td>ACHC - State Board Inspections</td>
<td>Rapid City</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>6/23/21</td>
<td>Fresco Community Pharmacy</td>
<td>Presho</td>
<td>Telepharmacy Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/24/21</td>
<td>Office Day</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>6/24/21</td>
<td>DOH COVID-19 Weekly Update</td>
<td>Sioux Falls</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>6/25/21</td>
<td>Board of Pharmacy Quarterly meeting</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
</tbody>
</table>
### Board of Pharmacy - Inspection Report

**2nd Quarter 2021**

<table>
<thead>
<tr>
<th>Date</th>
<th>Destination</th>
<th>City</th>
<th>Purpose</th>
<th>PDMP/ Narc Destruction etc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>4/14/21</td>
<td>What to Expect When the DEA Visits Your Hospital or Healthcare Facility</td>
<td>Groton</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>4/15/21</td>
<td>DOH Weekly COVID Call</td>
<td>Aberdeen</td>
<td>Virtual Meeting</td>
<td></td>
</tr>
<tr>
<td>5/6/21</td>
<td>DOH Weekly COVID Call</td>
<td>Groton</td>
<td>Virtual Meeting</td>
<td></td>
</tr>
<tr>
<td>5/11/21</td>
<td>EPA Subpart P-What You Need to Know</td>
<td>Groton</td>
<td>Webinar</td>
<td></td>
</tr>
<tr>
<td>5/18/21</td>
<td>Marshall County Hospital</td>
<td>Britton</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>5/25/21</td>
<td>Dosch Family Pharmacy</td>
<td>Eureka</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>5/25/21</td>
<td>Eureka Community Health Services Avera</td>
<td>Eureka</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>6/14/21</td>
<td>Walmart 10-1500</td>
<td>Watertown</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/16/21</td>
<td>Walgreens 10007</td>
<td>Watertown</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/16/21</td>
<td>Airgas</td>
<td>Watertown</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>6/16/21</td>
<td>Pharmerica</td>
<td>Watertown</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>6/17/21</td>
<td>Avera St. Luke's Hospital</td>
<td>Aberdeen</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>6/17/21</td>
<td>Dakota Plains Surgical</td>
<td>Aberdeen</td>
<td>Inspection</td>
<td></td>
</tr>
<tr>
<td>6/22/21</td>
<td>HyVee 1871</td>
<td>Watertown</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/23/21</td>
<td>Avera McKennan Campus Pharmacy</td>
<td>Sioux Falls</td>
<td>Inspection</td>
<td>PDMP</td>
</tr>
<tr>
<td>6/24/21</td>
<td>Board of Pharmacy Office</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
<tr>
<td>6/24/21</td>
<td>Department of Health Bi-monthly COVID Call</td>
<td>Sioux Falls</td>
<td>Virtual Meeting</td>
<td></td>
</tr>
<tr>
<td>6/25/21</td>
<td>Quarterly BOP Meeting</td>
<td>Sioux Falls</td>
<td>Meeting</td>
<td></td>
</tr>
</tbody>
</table>
South Dakota Prescription Drug Monitoring Program Update
June 25, 2021

What's New at the SD PDMP?

- RxCheck Hub sharing set up with NE – currently share with 36 other PDMPs
- Statewide Gateway Integration Project 'In Production'
  - Avera Health, Sanford Health, and Monument Health
  - SD Health Link
  - 4 Hospitals
  - 10 Clinics
  - 76 Pharmacies
  - Appriss' Communication Campaign led to 22 Integration Requests
- License Integration Project Status
  - Pharmacy Board, Nursing Board, Optometry Board, Podiatry Board, and Dentistry Board are live with auto reverification and auto-approval of new accounts
  - Medical Board – participation still pending

MedDrop Program Update

- Receptacles in SD Retail Pharmacies and Hospitals
  - 2017 – 2 in place
  - 2018 – 12 in place
  - 2019 – 38 in place
  - 2020 – 83 in place (added 6 HyVee locations to “Automatic Reload”)
  - 2021 – 84 in place – Davis Pharmacy new site as of May
  - 90 sites serviced by the BOP's program
- Pounds Returned for Destruction
  - 2018 – 1,496 lbs.
  - 2019 – 4,287 lbs.
  - 2020 – 7,302 lbs.
  - Total Since Inception – 17,309 lbs.

Virtual Presentations Given/Events Attended

- SDSHP Annual Conference BOP/PDMP Presentation
- SDSU College of Pharmacy P2 Class PDMP Presentation
- USD Sanford School of Medicine Resident Quality and Safety Boot Camp PDMP Presentation
- SD Dental Association BOP/PDMP Presentation
- Sanford Resident Orientation PDMP Presentation

Upcoming Events
- KS BOP/CDC OD2A Peer to Peer Learning Collaborative – August 2021 in Kansas City, MO

<table>
<thead>
<tr>
<th>Year 2020 Top Ten Controlled Substances (CS) to SD Patients</th>
<th>RXs</th>
<th>Quantity</th>
<th>Days of Supply</th>
<th>Avg QuantRX</th>
<th>2019 Rank</th>
<th>2018 Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYDROCODONE BITARTRATE/ACETAMINOPHEN</td>
<td>145,862</td>
<td>8,103,653</td>
<td>1,903,727</td>
<td>56</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>TRAMADOL HCL</td>
<td>117,316</td>
<td>7,492,916</td>
<td>2,028,466</td>
<td>64</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>DEXTROAMPHETAMINE SULF-SACCHARATE/AMPHETAMINE SULF-ASPARTATE</td>
<td>84,146</td>
<td>3,850,001</td>
<td>2,515,776</td>
<td>40</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>LORAZEPAM</td>
<td>89,083</td>
<td>3,624,901</td>
<td>1,822,438</td>
<td>43</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>CLONAZEPAM</td>
<td>74,180</td>
<td>4,044,728</td>
<td>2,177,195</td>
<td>55</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>ZOLPIDEM TARTRATE</td>
<td>72,381</td>
<td>2,494,954</td>
<td>2,484,886</td>
<td>34</td>
<td>6</td>
<td>4</td>
</tr>
<tr>
<td>METHYLPHENIDATE HCL</td>
<td>58,186</td>
<td>2,558,605</td>
<td>1,778,946</td>
<td>43</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>ALPRACOLOM</td>
<td>51,106</td>
<td>2,736,628</td>
<td>1,331,811</td>
<td>53</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>OXYCODONE HCL</td>
<td>48,142</td>
<td>2,278,177</td>
<td>675,628</td>
<td>57</td>
<td>9</td>
<td>9</td>
</tr>
<tr>
<td>USDEXAMFETAMINE DIMESYLATE</td>
<td>40,550</td>
<td>1,232,607</td>
<td>1,219,092</td>
<td>30</td>
<td>10</td>
<td>10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical Alerts Measures</th>
<th>Total Alerts for All Prescribers</th>
<th>Total Prescribers Receiving Alerts</th>
<th>Prescriber/Dispenser Alerts</th>
<th>Daily Active MME Threshold Alerts</th>
<th>Opioid &amp; Benz Threshold Alerts</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018 Totals</td>
<td>90,879</td>
<td>13,029</td>
<td>515</td>
<td>34,592</td>
<td>55,772</td>
</tr>
<tr>
<td>2019 Totals</td>
<td>72,983</td>
<td>12,250</td>
<td>407</td>
<td>25,949</td>
<td>46,607</td>
</tr>
<tr>
<td>2020 Totals</td>
<td>66,911</td>
<td>11,579</td>
<td>229</td>
<td>22,389</td>
<td>44,313</td>
</tr>
</tbody>
</table>

SD PMP AWARXe Users as of Q1 2021

- Pharmacists, 1,235
- Prescriber Delegates, 810
- Investigators, 157
- Other, 13
- Prescribers, 5,874
SPRING DISTRICT MEETINGS
Due to continued COVID-19 protocols, Spring District meetings again took place via Zoom. This Spring meeting is the most important district meeting of the year, as the Fall meeting is now optional. Districts addressed many important items, including the election or re-election of district officers; nominations for the state association board of directors; and the recognition and nomination of worthy pharmacists, reps and technicians to be considered by the Executive Board for the awards presented at our annual meeting. We look forward to restoring these to district meetings to in-person functions in 2022.

SDPhA BOARD RETREAT | JUNE 4-5
After more than a year of meeting only via Zoom due to the pandemic, the SDPhA board was able to meet in person for the Annual retreat. The board always uses this time together to tackle some of the association’s biggest tasks, such as strategic planning and legislative goals for the coming year, continuing education opportunities and agenda items for the annual meeting and convention, setting the budget, and selection of annual award winners. After so many months of meeting only via Zoom, it was great to collaborate and fellowship physically together in the same room.

SOUTH DAKOTA PHARMACISTS ASSOCIATION ANNUAL MEETING
As previously announced, SDPhA will move forward with the 135th annual meeting in person Sept. 17-18 in Spearfish, SD. After carefully evaluating the needs survey sent to nearly 100 potential sponsors and exhibitors, the board decided to move forward with an in-person event. In order to best meet the needs of those vendors who are able to travel, SDPhA will follow the CDC guidelines for large gatherings, whatever they may be, at the time of the event. Online registration will launch with the launch of the new website, and vendor packets are underway. We look forward to bringing our pharmacists, technicians, students and industry partners back together again, and celebrating the pharmacy superheroes who stood (and continue stand) on the front line of the COVID-19 pandemic.

MARIJUANA INTERIM LEGISLATIVE STUDY
With IM 26 (medical marijuana) set to go into effect July 1, and everyone awaiting the South Dakota State Supreme Court decision on Amendment A (recreational or adult use marijuana) the legislature is working through a summer study tackling both issues. SDPhA has been actively engaged in this process. The first interim study committee meeting took place May 26-27. At the request of the chairman, SDPhA provided testimony from the pharmacy perspective. Jeremy Daniel, PharmD, BCPS, BCPP, provided committee members with exceptional insight into the clinical facts around medical marijuana, its actual effectiveness on certain disease states, and how it interacts with medications. SDPhA has not taken a position on this issue, but has worked hard to position pharmacists as the medication experts and a trusted resource. Throughout testimony, there was a repeated call, particularly from law enforcement, that since IM 26 labels marijuana as medicine, it should be treated as such, and handled through the same distribution channels. We’ve had
numerous conversations and calls with lawmakers and law officers explaining that, to the Drug Enforcement Agency (DEA), marijuana remains a Schedule I drug. That means the consequences to a pharmacist/pharmacy could be devastating. These conversations are ongoing, as is the interim study, and we will continue to participate in the process. Secretary Kim Malsam-Rysdon has said she anticipates the Department of Health will start issuing certification cards to patients and caregivers by mid-November.

**IM 26 OVERSIGHT COMMITTEE**

Initiated Measure 26 requires the creation of an oversight committee, and South Dakota pharmacists will have a seat at the table. On June 2, Eric Grocott, a past president of SDPhA, was appointed to the 14-member oversight committee by the executive board of the Legislative Research Council. The committee’s role is to review and advise on medical marijuana in South Dakota.

**DEA TAKE-BACK EVENT | APRIL 24**

Please visit https://takebackday.dea.gov/sites/default/files/NTBI20%20Totals.pdf to view full take-back event totals and information. We continue to help spread the word about these opportunities and work to encourage pharmacist participation in these locally-held events. We also continue to work with pharmacists and the BOP to promote the year-round pharmaceutical disposal receptacles located throughout the state. If you have a story you’d like to share about either to aid in that promotion, please contact our office.

**PBM REFORM WORKGROUP**

The Supreme Court’s unanimous ruling in the Rutledge case set off a flurry of legislative activity in many states, including South Dakota. While the ruling does not end DIR fees or unfair reimbursement, the Court held that the Employee Retirement Income Securities Act of 1974 (ERISA) does NOT prevent states from regulating the pricing or rates that Pharmacy Benefit Managers (PBMs) pay pharmacies for dispensing prescriptions to beneficiaries on ERISA plans (plans that are sponsored by a private employer or union). In other words, it means state laws that address pricing and rates apply to ERISA plans, which PBMs had claimed were exempt from the state laws. Provisions such as reimbursements to pharmacies, MAC transparency, and the ability to decline to dispense prescriptions in the face of negative reimbursements all fall within the state’s authority to regulate ERISA plans. Additionally, ERISA plans should be subject to reimbursement floors and prohibitions on retroactive claim reductions.

SDPhA has worked diligently for many years to educate lawmakers on the complexities of PBMs. The intricacies of the process are not always easily understood, but in general, our lawmakers have always known that when SDPhA comes to talk to them about something – it’s because there’s a great need. Gag clause laws, clawbacks, DIR fees, and the 340B program have all been addressed through legislation in recent legislative sessions. But, as always, the PBMs continue to find workarounds. Now, the Rutledge ruling gives us more backing to strengthen our laws. SDPhA is working together with other stakeholders to establish the best path forward to tackling this issue in the 2022 legislative session. Workgroup meetings are already underway, and SDPhA has also met with representatives of the state to gauge their interest and support. It seems quite evident that it will take a concentrated effort from all parties to garner the needed support. We anticipated this challenge, and know our pharmacists will rise with us to meet it. We look forward to sharing more details on these efforts at the annual meeting in Spearfish.

**WILKE V. PCMA**

On a similar note, SDPhA has signed on to participate as Amicus Curiae in PCMA vs. Wilke (8th Cir.). In 2017, the State of North Dakota enacted comprehensive legislation to regulate many practices of pharmacy benefit managers (PBMs) that the State perceived as abusive to patients and pharmacies. Among other things, North Dakota regulates the disclosure of the fees that PBMs charge pharmacies and the use by PBMs of esoteric accreditation and certification standards that
restrict pharmacy access. In addition, North Dakota limits arbitrary and costly restrictions in PBM contracts designed to steer patients to PBM-affiliated pharmacies, and it has prohibited copay claw-backs and the use of gag clauses to prevent pharmacists from disclosing drug price information to patients.

Before North Dakota’s law went into effect, the Pharmaceutical Care Management Association (PCMA), the lobbying arm of the PBM industry, sued to prevent the State from enforcing its PBM law. PCMA’s lawsuit claimed that two federal laws, the Employee Retirement Income Security Act of 1974 (ERISA) and Medicare Part D, prevent North Dakota from regulating PBMs. The U.S. Court of Appeals for the Eighth Circuit agreed, invalidating North Dakota’s PBM law in its entirety. However, in light of the Rutledge case decision, the Supreme Court issued an order granting North Dakota’s petition for review, vacated the Eighth Circuit’s decision, and sent the case back to the Eighth Circuit for further consideration.

According to PCMA, Rutledge is limited to State laws that regulate the rates at which PBMs reimburse pharmacies. PCMA argues that ERISA and Medicare Part D preempt any other State law regulating PBMs. An adverse decision in Wilke could severely limit the States’ ability to regulate PBMs.

South Dakota, Like Arkansas and North Dakota is in the 8th circuit, so what happens with these cases sets a precedent for how we move forward addressing PBMs in our state.

COMMERCIAL AND LEGISLATIVE (C & L) FUND

All of this legislative work leads us here – to the very important role the Commercial and Legislative Fund plays in our ability to move forward with PBM reform, and other legislative priorities. The pandemic has given us a very unique opportunity to showcase the vital role pharmacists play in the health and well-being of our communities, and is opening key doors for the profession. We work hard daily to position ourselves at the table that allows us access to opportunities as they arise. That is why the C & L Fund is so very important.

The C&L Fund is separate from the SDPhA general accounts. It is used to support the legislative work we do, and relies nearly exclusively on contributions. Lobbying is an expensive, but necessary function, so the importance of this fund cannot be overstated. It is critical, and assists SDPhA in the protection and promotion of the profession during the Legislative Session. Unfortunately, the C&L fund is reaching a critically low level.

As we roll out the new website, and mount an effort to strengthen our state PBM laws, you will see more focus on sustaining this essential fund. We will highlight the work we do with it, how you can contribute, and frankly, why it’s more important now than ever to do so. We need support to continue to ensure our seat at the table in Pierre. You can expect to see reminders in your email and on social media to contribute. You can easily contribute at sdpha.org, or send a check to SDPhA, P.O. Box 518. Pierre, SD 57501. We need to have the financial resources available to fully swing into action on bills and policy that affect pharmacists in South Dakota. During 2020/2021, we expended around $12,000 to fund lobbying activities. Fund contributions again fell well short of the amount needed to continue to support a lobbyist. Simply put, we can’t retain our Lobbyist, Bob Riter and his partner Lindsey Riter-Rapp without this support. Thank you to all those who have, and continue to support our efforts!

SDPHA WEBSITE REBUILD

The final details are nearly complete, and after a lot of work to establish a new payment gateway and credit card processor, we are thrilled to share that SDPhA will launch a completely new, updated, and much more user-friendly website! The new website features a completely mobile-responsive and modern design, and a fully upgraded and intuitive user experience – from convention registration to contacting us and everything in between. The new website will feature a forms library which will play a key role in streamlining conventions and eliminating the use of so much
paper moving forward. Another key feature is an area we call the Action Center. That’s where you’ll find all the issues we’re working on at the federal and state level. It’ll also house the new bill tracker we launched this legislative session, and it will even allow for you to opt in to text alerts about key issues, to let you know when to contact your legislators on an issue of importance to the profession. The Action Center will be a vital piece of our communications on legislative issues, and we are excited for you to see it, and put it into action yourself. The launch of the new website will coincide with the opening of convention registration, and we are thrilled about both!

SCAPP | SDSU APhA – ASP CHAPTER
We continue to work closely with SDSU and the student pharmacists, and we are thrilled to welcome a new student liaison to the SDPhA board. Kaylee Ayers will join Katelynn Jackson in that role. The student liaisons have done an amazing job keeping us apprised of activities, and the SDPhA board remains committed to supporting the students in every way possible. We look forward to getting back to in-person activities with the SCAPP members such as convention attendance (free of charge), rooms for convention and Legislative Days, and support for the Back-to-School Picnic, Pharmacy Days, and American Pharmacists Month activities.

CORONOVIRUS (COVID-19)
Vaccination Distribution / Pandemic Response
As millions of Americans receive the COVID-19 vaccine, including more than 361,000 (as of the date of this report) in South Dakota, pharmacists continue to play a key part in vaccine rollout across the state. Hospital pharmacists have been vital in meeting the initial challenges of vaccine distribution, handling, storage, standing up vaccination clinics, and finally, getting shots in arms. Community retail pharmacists across the state also answered the call to prepare to vaccinate the state’s general population. The DOH website has a complete list of Federal Pharmacy Program locations. Distribution to independent and smaller community pharmacies continues to present challenges. Storage, transportation and minimum orders have complicated this process, and we continue to participate in conversations weekly with the South Dakota Department of Health (SD DOH) on opportunities to further engage our pharmacists who are ready, willing, and able to provide vaccinations to those in their communities.

Communication
We encourage everyone to continue to closely watch your email, the SDPhA Facebook Group page and the SDPhA website for updates and important pandemic and vaccine-related information. Even as the pandemic wanes, communication and offering assistance to our pharmacists and pharmacies continues to be a top priority for SDPhA. Pharmacies and pharmacists are critical to the well-being of the citizens of South Dakota, not only in dealing with COVID-19, but also in our residents’ ongoing care. The new website will continue to house COVID-19 Resources. We post "news" related information on our Facebook Group page. That includes pertinent updates from CMS, HHS, the FDA, DSS, etc. We continue to send out emails to all as appropriate. We greatly appreciate the ongoing strong and open channels of communication with several state agencies, our congressional delegation and the South Dakota Board of Pharmacy on items of concern to pharmacists as well as the public health and safety.

Advocacy and Engagement
While the initial frenzied pace of the pandemic response has slowed, we continue to engage with the BOP, South Dakota Department of Health, and other state partners on behalf of pharmacists where appropriate. Meantime at the federal level, we remain in close communication with our Congressional delegation, and continue to keep apprised of, and engaged where suitable, in the all the rapidly moving parts on Capitol Hill. Advocacy efforts now focus on maintaining the flexibilities extended to pharmacists by the federal government, while continuing to advocate for change that allows pharmacists to practice to the full scope of their expertise. This has included not only work on emergency provider status, but on immunizations, testing, payment, compounding and funding programs as well. The National Alliance of
State Pharmacy Associations (NASPA) also continues to work on our behalf with many of our national partners on matters of concern and importance to pharmacists.

**NCPA CONGRESSIONAL PHARMACY FLY-IN | APRIL 19-21**

For the second year in a row, SDPhA participated in the NCPA fly-in without leaving the office! This year NCPA arranged virtual visits between associations, members and congressional delegations. This is a very welcome opportunity to meet with our South Dakota Congressional Delegation to secure support for various federal pieces of legislation affecting pharmacy, as well as bring them up to speed on pharmacy issues here at home. Jessica Strobl, SDPhA Treasurer joined Amanda Bacon in representing the association in these conversations.

**NASPA LEADERSHIP RETREAT | APRIL 19-21**

Going virtual does have some advantages – typically budget and time constraints would preclude SDPhA from participating the in the National Alliance of State Pharmacy Associations (NASPA) leadership retreat for executives and presidents-elect. However, this year the event was held virtually, allowing Kristen Carter, SDPhA President-Elect and Amanda Bacon, Executive Director, to participate in the two-day event. This was truly a great opportunity for collaboration among attendees from all the states. It was also a chance for our presidents-elect to learn more about the nuts-and-bolts of the day-to-day work in association management, especially as it relates to finances in the non-profit sector. We hope some sort of virtual option remains available for this event in the future.

**NATIONAL BILLS**

SDPhA remains engaged in a variety of ways in various national efforts on key topics directly impacting our pharmacists such as: COVID-19 related bills, DIR fee relief, PBM reform, pricing transparency, dispensing requirements, improvements to Medicare, prescription drug misuse and abuse, compounding guidance and provider status. The list that follows are the most recent major bills currently related to the aforementioned issues.

**NEW! H.R. 3554/S. 1909 | To amend title XVIII of the Social Security Act to reform requirements with respect to direct and indirect remuneration under Medicare part D, and for other purposes, or the Pharmacy DIR Reform to Reduce Senior Drug Costs Act**

The Congressional Research Service has not yet developed a summary for this bill. The bill aims to create requirements for Part D plans to address DIR fees by: Requiring pharmacy negotiated price concessions, payment, and fees to be included at the point of sale for Medicare Part D prescriptions; Requiring disclosure to the pharmacy of price concessions and incentive payments; and establishing standardized pharmacy performance metrics. This bill was introduced 5/25/2021, and currently has 16 co-sponsors. It was referred to the Committee on Energy and Commerce in addition to the Committee on Ways and Means.

**NEW! H.R. 2608 | Ensuring Seniors Access to Local Pharmacies Act**

This bill establishes several requirements for prescription drug plans under the Medicare prescription drug benefit. Specifically, the bill requires prescription drug plans to allow any pharmacy located in a health professional shortage area, a medically underserved area, or a rural area to be included as an in-network pharmacy if the plan already has other in-network pharmacies in the same area. The bill also establishes certain standards for prescription drug plans regarding pharmacy reimbursements and related disclosures. Among other things, the bill prohibits prescription drug plans from reimbursing a pharmacy in an amount that is less than the amount the pharmacy benefits manager (PBM) reimburses an affiliated pharmacy (i.e., a pharmacy that has a shared ownership interest with the PBM) for the same services. This bill was introduced 4/15/2021 and has 15 co-sponsors. It was referred to the Committee on Energy and Commerce in addition to the Committee on Ways and Means.
NEW! H.R. 2759/S. 1362 | Pharmacy and Medically Underserved Areas Enhancement Act
A summary is in progress on this bill which aims to enable Medicare beneficiaries access to pharmacist-provided services under Medicare Part B by amending section 1861(s)(2) of the Social Security Act to recognize pharmacists as providers. Pharmacist-provided services would be reimbursable under Medicare Part B only if provided in areas of the country that HRSA defines as medically underserved areas (MUAs), medically underserved populations (MUPs), or health professional shortage areas (HPSAs). The legislation does not expand services beyond each state’s already existing scope of practice. Pharmacist services would be reimbursed at 85% of the physician fee schedule. This bill was introduced 4/22/2021 and was referred to the Committee on Energy and Commerce in addition to the Committee on Ways and Means. It currently has 31 co-sponsors.

S. 298 | Pharmacy Benefit Manager Accountability Study Act of 2021
This bill requires the Government Accountability Office to study the role pharmaceutical benefit managers play in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes. It currently has one cosponsor. This bill was referred to the Committee on Health, Education, Labor and Pensions 2/8/2021.

S. 920 | To Amend the Federal Food, Drug, and Cosmetic Act to Allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals.
The full text of this bill is not yet available online. It was introduced just two days before the filing of this report. It does have 21 co-sponsors. It was referred to the committee on Health, Education, Labor and Pensions Subcommittee on Primary Health and Retirement Security 3/23/2021. There is a similar bill in the House – H.R. 2181.

S. 259 | Safe and Affordable Drugs from Canada Act of 2021
This bill requires the Food and Drug Administration (FDA) to allow for the personal importation of prescription drugs from Canada in certain instances. Such a drug must (1) be purchased from an approved Canadian pharmacy and dispensed by a pharmacist licensed in Canada; (2) be purchased by an individual for personal use only and in quantities not to exceed a 90-day supply; (3) be filled using a valid prescription from a physician licensed in a U.S. state; and (4) have the same active ingredients, route of administration, dosage form, and strength as an FDA-approved drug. Certain types of drugs may not be imported under this program, such as controlled substances, biological products, or intravenously injected drugs. An approved pharmacy under this program must be located and licensed in Canada and meet additional requirements, such as participation in ongoing and comprehensive quality assurance programs. The bill has 12 cosponsors. It was referred to the Committee on Health, Education, Labor, and Pensions 2/4/2021. H.R. 832 is the related House Bill.

H.R. 1319 | American Rescue Plan Act of 2021
This bill provides additional relief to address the continued impact of COVID-19 (i.e., coronavirus disease 2019) on the economy, public health, state and local governments, individuals, and businesses. Specifically, the bill provides funding for
- agriculture and nutrition programs, including the Supplemental Nutrition Assistance Program (SNAP, formerly known as the food stamp program);
- schools and institutions of higher education;
- child care and programs for older Americans and their families;
- COVID-19 vaccinations, testing, treatment, and prevention;
- mental health and substance-use disorder services;
- emergency rental assistance, homeowner assistance, and other housing programs;
- payments to state, local, tribal, and territorial governments for economic relief;
- multiemployer pension plans;
- small business assistance, including specific programs for restaurants and live venues;
programs for health care workers, transportation workers, federal employees, veterans, and other targeted populations;
international and humanitarian responses;
tribal government services;
scientific research and development;
state, territorial, and tribal capital projects that enable work, education, and health monitoring in response to COVID-19; and
health care providers in rural areas.

The bill also includes provisions that

- extend unemployment benefits and related services;
- make up to $10,200 of 2020 unemployment compensation tax-free;
- make student loan forgiveness tax-free through 2025;
- provide a maximum recovery rebate of $1,400 per eligible individual;
- expand and otherwise modify certain tax credits, including the child tax credit and the earned income tax credit;
- provide premium assistance for certain health insurance coverage; and
- require coverage, without cost-sharing, of COVID-19 vaccines and treatment under Medicaid and the Children's Health Insurance Program (CHIP).

This bill has 18 related bills. South Dakota's entire Congressional Delegation voted against this bill. The American Rescue Plan Act became Public Law No: 117-2 3/11/2021

H.R 6800 | HEROES Act – 116th Congress
This bill responds to the COVID-19 outbreak and its impact on the economy, public health, state and local governments, individuals and businesses. In terms of healthcare, it establishes a fund to award grants to provide pandemic premium pay for essential workers, modifies and expands the Paycheck Protection Program (which provides loans and grants to small businesses and nonprofit organizations), provides funding and establishes requirements for COVID-19 testing and contract tracing, eliminates cost-sharing for COVID-19 treatments. It also expands several programs and policies including those regarding Medicare and Medicaid, health insurance. This bill narrowly passed the House 5/15/2020. Rep. Dusty Johnson R-SD did not support the legislation. Hearings were held on this bill in the Senate Committee on Small Business and Entrepreneurship 7/23/2020.

This bill authorizes the Centers for Disease Control and Prevention (CDC) to award grants for testing, contact tracing, monitoring, and other activities to address COVID-19 (i.e., coronavirus disease 2019). Entities such as federally qualified health centers, nonprofit organizations, and certain hospitals and schools are eligible to receive such grants. In awarding the grants, the CDC shall prioritize applicants that (1) operate in hot spots and medically underserved communities, and (2) agree to hire individuals from the communities where grant activities occur. This bill has 72 co-sponsors and was referred to the House Committee on Energy and Commerce 5/1/2020.

PHARMACY TECHNICIAN UNIVERSITY (PTU)
Technicians – finding them, training them, and keeping them is becoming an even more pressing issue now than perhaps maybe ever before. PTU is helping us help our pharmacies answer that call, and our slate of trainings and tools continues to grow. We are pleased to continue to offer low-cost access to this online training module, and to further enhance the programs we offer through it. To date SDPhA has enrolled more than 106 participants. Not only were we one of the first Associations in the nation to work with Therapeutic Research Center (TRC) and PTU in this manner, we are now working on a partnership with them that will make us one of four state associations in the nation to provide an enhanced array of services nationwide.
We are also enhancing our partnership with the DIAL Virtual program by working with them to elevate the promotion of the pharmacy technician program they offer in the schools (which uses our PTU platform). Working together with school principals and administrators we hope to identify more students interested in the field, and increase access to the program. During the 2020-2021 school year, we had 8 students from various South Dakota High Schools enrolled. We already have 4 on the list for this Fall. We greatly appreciate the pharmacists who have stepped up in communities across the state to work with the DIAL program and these students. This is an exceptional opportunity to introduce the profession into the school systems, and we are grateful for everyone working together who makes it happen.

Just a reminder, the Therapeutic Research Center - PTU 101 module we administer qualifies as a PTCB-Recognized Education/Training Program of the CPhT program, and upon completion, allows participants to sit for the certification exam. In addition to PTU 101, we now offer four additional training modules through TRC:

- PTU Elite: Immunizations
- PTU Elite: Math Mastery – Community Pharmacy
- PTU Elite: Compounded Sterile Preparation Technician Program
- PTU Elite: Soft Skills Program.

For more details and enrollment information, contact Amanda Bacon at amanda@sdpha.org or (605) 224-2338.

**HEALTH PROFESSIONAL ASSISTANCE PROGRAM (HPAP)**

The passage of SB4 in 2021 means changes to some of the requirements for HPAP program administration. We continue to appreciate the open communication with the Board of Pharmacy on what this may mean for the future of the program. Our association continues to support HPAP, and saw no changes in the billing for FY 20201-2022. A pharmacist may access the program by self-referral, board referral, or referral from another person or agency, employer, coworker or family member.

**THE SOUTH DAKOTA PHARMACIST**

Communicating with our members quickly and effectively is extremely critical to the success of the Association. The South Dakota Pharmacist continues a quarterly electronic distribution. You can also find it posted with past issues on our website. It always offers 1.5 hours of CE, and provides a source of communication for the association on rules, legislative issues and education that affect pharmacy practice.

**SOCIAL MEDIA / EMAIL BLASTS**

We continue to work on our social media footprint. This is something we consider vital to our work of representing the pharmacy profession through advancing patient care, enhancing the public awareness and serving in the best interest of public health and pharmacy. It’s also sometimes a challenge with a one-man office. There are a lot of things to tackle in a day, and sometimes the social media posts fall victim to the more urgent issues of any given day. That being said, the board is committed to this communication, as we know it’s effective — so expect to see more posts from them on our platforms, too.

Here’s what’s important to know about each of our social spaces:

- Our Facebook and Instagram (Instagram remains a work in progress) are primarily consumer-driven health messages. These posts are intended to give you easy access to content you can in turn share on your social channels to help engage your patients and the general public.
- The SDPhA Member News and Announcements Facebook Group page is where you will now find industry news, SDPhA event and meeting information, and legislative updates as warranted.
• LinkedIn gives us an additional forum to gather and share news impacting the pharmacy profession. The page is established. Look for increased messaging there soon.

Please like, follow, share and engage with us – that’s what makes these tools effective.

ASSOCIATION MANAGEMENT ROTATION
SDPhA is pleased to welcome Benjamin Ostebee for an APPE in Association Management late this summer. Ostebee is scheduled to begin work with Amanda Bacon and the SDPhA Board of Directors Aug. 23, and will conclude her rotation Sept. 24. We are thrilled to work with student pharmacists who want to take a deeper dive into this unique field of management, learning the day-to-day operations, the complexities of running an association, and the many management aspects unique to associations and legislative work. We look forward to the opportunity to work with more students in the future.

SDPHA OFFICE UPDATE
There hasn’t been the typical moment to catch our breath coming out of legislative session this year. Continued work regarding the pandemic, national advocacy work, the legislative Interim committee, and laying the groundwork for enhanced PBM efforts, as well as now planning for a live convention in September – have meant an extremely busy start to the “off-season” for the SDPhA office. I appreciate the opportunity to share our recent work with you, and continue to greatly appreciate the spirit of collaboration I have received from the BOP. It will take all of us standing together in the coming months as we work through the many issues that lie ahead.

Kind Regards,

Amanda Bacon
Executive Director
South Dakota Pharmacists Association
### Ordinary Income/Expense

#### Income
- **SD Board of Pharmacy Transfer**
  - Jul 1, '20: 202,400.00
  - Budget: 199,000.00
  - % of Budget: 101.7%
- **Associate Member**
  - Jul 1, '20: 500.00
  - Budget: 200.00
  - % of Budget: 250.0%
- **District Dues**
  - District 9 - Yankton: 15.00
  - District 8 - Watertown: 80.00
  - District 7 - Sioux Falls: 120.00
  - District 2 - Black Hills: 160.00
  - District 1 - Aberdeen: 140.00
  - Total District Dues: 515.00
- **Student Membership**
  - Jul 1, '20: 500.00
  - Budget: 1,540.00
  - % of Budget: 140.0%
- **Total Membership**
  - Jul 1, '20: 204,955.00
  - Budget: 200,300.00
  - % of Budget: 102.3%
- **Corp Endorsements**
  - NASPA-PQC Endorsement: 300.00
  - Career Center Endorsement: 274.50
  - PAAS Endorsement: 306.00
  - PMG Endorsement: 13,549.00
  - Total Corp Endorsements: 14,429.50
- **Interest/Dividends**
  - Jul 1, '20: 292.67
  - Budget: 3,000.00
  - % of Budget: 9.8%
- **Convention Income**
  - PhRMA Education Grant: 5,000.00
  - Convention Sponsor: 500.00
  - Exhibitors: 3,500.00
  - Registrations: 10,725.00
  - Student Sponsorship: 50.00
  - Total Convention Income: 19,775.00
- **Total Income**
  - Jul 1, '20: 239,452.17
  - Budget: 235,750.00
  - % of Budget: 101.6%

#### Expense
- **Legislative**
  - Jul 1, '20: 240.00
  - Budget: 0.00
  - % of Budget: 100.0%
- **American Pharmacists Month**
  - Jul 1, '20: 1,830.00
  - Budget: 1,850.00
  - % of Budget: 98.9%
- **Accounting/Tax Prep**
  - Jul 1, '20: 4,361.84
  - Budget: 4,800.00
  - % of Budget: 90.9%
- **Salary & Benefits**
  - Payroll Taxes: 4,354.11
  - Payroll Expense: 38.65
  - Executive Director: 56,874.93
  - Insurance: 9,908.25
  - Retirement: 3,412.50
  - Total Salary & Benefits: 74,588.44
- **Advertising**
  - Jul 1, '20: 0.00
  - Budget: 3,000.00
  - % of Budget: 0.0%
- **Dues/Subscriptions**
  - Jul 1, '20: 2,150.00
  - Budget: 3,300.00
  - % of Budget: 65.2%
- **Technology/Net/Software**
  - Jul 1, '20: 19,663.72
  - Budget: 11,000.00
  - % of Budget: 178.8%
- **Furniture/Copier/Assets**
  - Jul 1, '20: 1,580.91
  - Budget: 2,300.00
  - % of Budget: 68.7%
- **Hlth Professionals Assist Prog**
  - Jul 1, '20: 20,000.00
  - Budget: 20,000.00
  - % of Budget: 100.0%
- **Insurance (D&O, Office)**
  - Jul 1, '20: 3,455.00
  - Budget: 3,600.00
  - % of Budget: 96.0%
- **Legal/Professional**
  - Jul 1, '20: 1,527.10
  - Budget: 5,000.00
  - % of Budget: 30.5%
- **Merchant Card Fees**
  - Jul 1, '20: 2,210.69
  - Budget: 2,300.00
  - % of Budget: 96.1%
- **Phone/Internet**
  - Jul 1, '20: 5,327.60
  - Budget: 4,500.00
  - % of Budget: 118.4%
- **Postage**
  - Jul 1, '20: 33.15
  - Budget: 150.00
  - % of Budget: 22.1%
- **Office Supplies**
  - Jul 1, '20: 738.36
  - Budget: 1,500.00
  - % of Budget: 49.2%
- **Publications & Printing (Exp)**
  - Journal: 3,641.04
  - Total Publications & Printing (Exp): 3,641.04
  - % of Budget: 113.8%
- **Scholarships**
  - Jul 1, '20: 0.00
  - Budget: 1,000.00
  - % of Budget: 0.0%
### SD Pharmacists Association
#### Profit & Loss Budget vs. Actual
**July 1, 2020 through May 18, 2021**

<table>
<thead>
<tr>
<th>Item</th>
<th>Jul 1, '20 - May 18, 21</th>
<th>Budget</th>
<th>% of Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rent</td>
<td>2,328.00</td>
<td>4,700.00</td>
<td>49.5%</td>
</tr>
<tr>
<td>Board Travel &amp; Meetings</td>
<td>1,688.14</td>
<td>20,000.00</td>
<td>8.4%</td>
</tr>
<tr>
<td><strong>Staff Travel</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In-State</td>
<td>0.00</td>
<td>5,000.00</td>
<td>0.0%</td>
</tr>
<tr>
<td>Out-of-State</td>
<td>0.00</td>
<td>6,000.00</td>
<td>0.0%</td>
</tr>
<tr>
<td><strong>Total Staff Travel</strong></td>
<td>0.00</td>
<td>11,000.00</td>
<td>0.0%</td>
</tr>
<tr>
<td>Convention Expense</td>
<td>3,669.93</td>
<td>10,000.00</td>
<td>36.7%</td>
</tr>
<tr>
<td>Misc Expense</td>
<td>193.24</td>
<td>500.00</td>
<td>3.8%</td>
</tr>
<tr>
<td><strong>Total Expense</strong></td>
<td>149,227.16</td>
<td>198,431.50</td>
<td>75.2%</td>
</tr>
<tr>
<td><strong>Net Ordinary Income</strong></td>
<td>90,225.01</td>
<td>37,318.50</td>
<td>241.8%</td>
</tr>
<tr>
<td><strong>Other Income/Expense</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Other Income</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTU Pass Thru Income</td>
<td>9,775.00</td>
<td>0.00</td>
<td>100.0%</td>
</tr>
<tr>
<td>C/L Contributions Pass Thru</td>
<td>150.00</td>
<td>0.00</td>
<td>100.0%</td>
</tr>
<tr>
<td>Individual C/L Contr.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>**Total C/L Contributions Pass Thru</td>
<td>150.00</td>
<td>0.00</td>
<td>100.0%</td>
</tr>
<tr>
<td><strong>Total Other Income</strong></td>
<td>9,925.00</td>
<td>0.00</td>
<td>100.0%</td>
</tr>
<tr>
<td><strong>Other Expense</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTU Pass Thru Exp</td>
<td>9,090.00</td>
<td>6,500.00</td>
<td>139.8%</td>
</tr>
<tr>
<td><strong>Total Other Expense</strong></td>
<td>9,090.00</td>
<td>6,500.00</td>
<td>139.8%</td>
</tr>
<tr>
<td><strong>Net Other Income</strong></td>
<td>835.00</td>
<td>-6,500.00</td>
<td>-12.8%</td>
</tr>
<tr>
<td><strong>Net Income</strong></td>
<td>91,060.01</td>
<td>30,818.50</td>
<td>295.5%</td>
</tr>
</tbody>
</table>
## SD Pharmacists Association C & L

### Revenue & Expenses Budget vs. Actual

**July 1, 2020 through May 18, 2021**

<table>
<thead>
<tr>
<th></th>
<th>Jul 1, ’20 - May 18, 21</th>
<th>Budget</th>
<th>% of Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Income</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C &amp; L Income</td>
<td>3,390.00</td>
<td>5,500.00</td>
<td>61.6%</td>
</tr>
<tr>
<td>Interest</td>
<td>672.44</td>
<td>0.00</td>
<td>100.0%</td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td>4,062.44</td>
<td>5,500.00</td>
<td>73.9%</td>
</tr>
<tr>
<td><strong>Expense</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Legislative Exp</td>
<td>4,792.50</td>
<td>12,450.00</td>
<td>38.5%</td>
</tr>
<tr>
<td><strong>Total Expense</strong></td>
<td>4,792.50</td>
<td>12,450.00</td>
<td>38.5%</td>
</tr>
<tr>
<td><strong>Net Income</strong></td>
<td>-730.06</td>
<td>-6,950.00</td>
<td>10.5%</td>
</tr>
</tbody>
</table>
36-11-6. Use of funds by Pharmacists Association--Approval of expenditures--Filing statement.

The board may, upon receipt, pay to the South Dakota Pharmacists Association eighty percent of all fees the board receives for renewals of certificates of registration as a pharmacist. The association shall use the funds for the following association activities to benefit the public and the profession: continuing education, matters related to registration standards for pharmacists, professional service standards, and general operating expenses related to the activities enumerated in this section. The association shall also use funds received to pay any legislated assessment to support a diversion program for chemically impaired pharmacists. Expenditures of funds shall be approved by the president and treasurer of the association. The association shall annually file in the office of the board an itemized statement of the receipts of the association and disbursements from the receipts.

MEMORANDUM OF UNDERSTANDING ADDRESSING CERTAIN DISTRIBUTIONS OF COMPOUNDED HUMAN DRUG PRODUCTS BETWEEN THE [insert STATE BOARD OF PHARMACY OR OTHER APPROPRIATE STATE AGENCY] AND THE U.S. FOOD AND DRUG ADMINISTRATION

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this information collection is 0910-0800 (expires 10/31/2023).

I. PURPOSE

This Memorandum of Understanding (MOU) establishes an agreement between the [insert State Board of Pharmacy or other appropriate State agency] and the U.S. Food and Drug Administration (FDA) regarding the distribution of inordinate amounts of compounded human drug products interstate\(^1\) and the appropriate investigation by the [insert State Board of Pharmacy or other appropriate State agency] of complaints relating to human drug products compounded in [insert State] and distributed outside such State.\(^2\) This is the MOU provided for by section 503A(b)(3)(B)(i) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) (21 U.S.C. 353a), and does not apply to veterinary drug products, biological products subject to licensure under section 351 of the Public Health Service Act (42 U.S.C. 262), and drugs that are compounded by outsourcing facilities under section 503B of the FD&C Act.

II. BACKGROUND

a. Section 503A of the FD&C Act describes the conditions that must be satisfied for human drug products compounded by a licensed pharmacist or licensed physician to be exempt from three sections of the FD&C Act requiring:


---

\(^{1}\) For purposes of this MOU, see the definitions of “inordinate amounts” and “distribution of compounded human drug products interstate” (also referred to as “distributed interstate”) in Appendix A.

\(^{2}\) As described herein, the State Board of Pharmacy or other appropriate State agency signatory is agreeing to take certain actions as described in Section III below. For example, if a State Board of Pharmacy signs the MOU, the State Board of Pharmacy agrees to take the actions described in Section III below with respect to drugs compounded by pharmacies in that State; in addition, the State Board of Pharmacy agrees that if it receives information about complaints or becomes aware of information about drugs compounded by physicians in the State and distributed interstate, it will forward the information to FDA and the appropriate State regulator of physicians as described in Section III.
2. Labeling with adequate directions for use (section 502(f)(1) (21 U.S.C. 352(f)(1)); and

3. FDA approval prior to marketing (section 505 (21 U.S.C. 355)).

b. To qualify for these exemptions, a compounded human drug product must, among other things,³ meet the conditions in section 503A(b)(3)(B) of the FD&C Act, under which the drug product is compounded in a State that:

1. Has entered into an MOU with FDA that addresses the distribution of inordinate amounts of compounded drug products interstate and provides for appropriate investigation by a State agency of complaints relating to compounded drug products distributed outside such State (section 503A(b)(3)(B)(i)); or

2. Has not entered into an MOU with FDA and the licensed pharmacist, licensed pharmacy, or licensed physician distributes (or causes to be distributed) compounded drug products out of the State in which they are compounded in quantities that do not exceed 5 percent of the total prescription orders dispensed or distributed by such pharmacy or physician (section 503A(b)(3)(B)(ii)).

c. Section 503A(b)(3) of the FD&C Act directs FDA to develop a standard MOU, in consultation with the National Association of Boards of Pharmacy (NABP), for use by the States in complying with section 503A(b)(3)(B)(i). This MOU is the standard MOU developed by FDA for this purpose.

III. SUBSTANCE OF AGREEMENT

a. Investigation of Complaints Relating to Compounded Human Drug Products Distributed Outside the State

1. The [insert State Board of Pharmacy or other appropriate State agency] will investigate complaints of adverse drug experiences and product quality issues⁴ relating to human drug products compounded at a pharmacy in [insert State] and distributed outside the State. Any investigations will be performed pursuant to the [insert State Board of Pharmacy or other appropriate State agency]’s established investigatory policies and procedures, including those related to prioritizing complaints, provided they are not in conflict with the terms of this MOU.

³ To qualify for the exemptions under section 503A, a compounder must obtain a prescription for an individually identified patient (section 503A(a) of the FD&C Act). This MOU does not alter this condition.

⁴ For purposes of this MOU, see the definitions of “adverse drug experience” and “product quality issue” in Appendix A.
2. Any investigations performed by the [insert State Board of Pharmacy or other appropriate State agency] under this MOU will include taking steps to assess (1) whether there is a public health risk associated with the compounded drug product; and (2) whether any public health risk associated with the product is adequately contained.

3. After the [insert State Board of Pharmacy or other appropriate State agency]’s investigation, if the complaint is substantiated, the [insert State Board of Pharmacy or other appropriate State agency], in accordance with and as permitted by State law, will take the action that the [insert State Board of Pharmacy or other appropriate State agency] considers to be appropriate and warranted to ensure that the relevant pharmacy investigates the root cause of the problem that is the subject of the complaint and undertakes sufficient corrective action to address any identified public health risk relating to the problem, including the risk that future similar problems may occur.

4. The [insert State Board of Pharmacy or other appropriate State agency] will maintain records of the complaint about adverse drug experiences or product quality issues relating to human drug products compounded at a pharmacy, the investigation of the complaint, and any response to or action taken as a result of the complaint, beginning when the [insert State Board of Pharmacy or other appropriate State agency] receives notice of the complaint. The [insert State Board of Pharmacy or other appropriate State agency] will maintain these records for at least 3 years. The 3-year period begins on the date of final action on a complaint, or the date of a decision that the complaint requires no action.

5. As soon as possible, but no later than 5 business days after receiving a complaint involving a serious adverse drug experience or serious product quality issue relating to a drug product compounded at a pharmacy and distributed outside the State, the [insert State Board of Pharmacy or other appropriate State agency] will, by submission to an Information Sharing Network5 or by email to StateMOU@fda.hhs.gov, provide FDA with the information described in the Submission and Disclosure of Information section of this MOU (section III.c.1.a.i-iii).6

---

5 For purposes of this MOU, see the definitions of “serious adverse drug experience,” “serious product quality issue,” and “Information Sharing Network” in Appendix A.
6 The information includes the following: (i) Name and contact information of the complainant, if available; (ii) Name and address of the pharmacy that is the subject of the complaint; and (iii) Description of the complaint, including a description of any compounded human drug product that is the subject of the complaint.
6. After the [insert State Board of Pharmacy or other appropriate State agency] concludes its investigation of a complaint assessed to involve a serious adverse drug experience or serious product quality issue relating to a drug product compounded at a pharmacy and distributed outside the State, the [insert State Board of Pharmacy or other appropriate State agency] will share with FDA, as described in the Submission and Disclosure of Information section of this MOU (section III.c.1.a.iv-v),\(^7\) the results of the investigation as permitted by State law.

7. If the [insert State Board of Pharmacy or other appropriate State agency] receives a complaint involving an adverse drug experience or product quality issue relating to a human drug product compounded by a physician and distributed outside the State, the [insert State Board of Pharmacy or other appropriate State agency] will notify the appropriate regulator of physicians within the State. The [insert State Board of Pharmacy or other appropriate State agency] will also notify FDA by submission to an Information Sharing Network or by sending an email to StateMOU@fda.hhs.gov with the information described in the Submission and Disclosure of Information section of this MOU (section III.c.2.a.-c), if available, as soon as possible, but no later than 5 business days, after receiving the complaint.

   b. Distribution of Inordinate Amounts of Compounded Human Drug Products Interstate\(^8\)

   1. For purposes of this MOU, a pharmacy has distributed an inordinate amount of compounded human drug products interstate if the number of prescription orders for compounded human drug products that the pharmacy distributed interstate during any calendar year is greater than 50 percent of the sum of:

      (i) the number of prescription orders for compounded human drug products that the pharmacy sent out of (or caused to be sent out of) the facility in which the drug products were compounded during that same calendar year; plus

      (ii) the number of prescription orders for compounded human drug products that were dispensed (e.g., picked up by a patient) at the

---

\(^7\) The information includes: (i) [Insert State Board of Pharmacy or other appropriate State agency]’s assessment of whether the complaint was substantiated, if available; and (ii) Description and date of any actions the [insert State Board of Pharmacy or other appropriate State agency] has taken to address the complaint.

\(^8\) The distribution of inordinate amounts of compounded human drug products interstate is a threshold for the [insert State Board of Pharmacy or other appropriate State agency] to identify and report certain information to FDA, not a limit on the distribution of compounded human drug products interstate.
facility in which they were compounded during that same calendar year.
2. On an annual basis, the [insert State Board of Pharmacy or other appropriate State agency] will identify, using surveys, reviews of records during inspections, data submitted to an Information Sharing Network, or other mechanisms available to the [insert State Board of Pharmacy or other appropriate State agency], pharmacies that distribute inordinate amounts of compounded human drug products interstate.

3. For pharmacies that have been identified as distributing inordinate amounts of compounded human drug products interstate during any calendar year, the [insert State Board of Pharmacy or other appropriate State agency] will identify, using data submitted to an Information Sharing Network or other available mechanisms, during that same calendar year:
   a. the total number of prescription orders for sterile compounded human drugs distributed interstate;
   b. the names of States in which the pharmacy is licensed;
   c. the names of States into which the pharmacy distributed compounded human drug products; and
   d. whether the State inspected for and found during its most recent inspection that the pharmacy distributed compounded human drug products without valid prescription orders for individually identified patients.

4. The [insert State Board of Pharmacy or other appropriate State agency] will, within 30 business days of identifying a pharmacy that has distributed inordinate amounts of compounded human drug products interstate, notify FDA of such pharmacy, through an Information Sharing Network or by email to StateMOU@fda.hhs.gov, and will include the

---

**Figure 1. Calculating an Inordinate Amount**

\[
\frac{A}{B} = X, \text{ where:}
\]

A = Number of prescription orders for compounded human drug products that the pharmacy distributed interstate during any calendar year

B = The sum of the number of prescription orders for compounded human drug products (i) that the pharmacy sent out of (or caused to be sent out of) the facility in which the drug products were compounded during that same calendar year; plus (ii) the number of prescription orders for compounded human drug products that were dispensed (e.g., picked up by a patient) at the facility in which they were compounded during that same calendar year

If \( X \) is greater than 0.5, it is an inordinate amount and is a threshold for certain information identification and reporting under the MOU.
information described in the Submission and Disclosure of Information section of this MOU (section III.c.1.b).

5. If the [insert State Board of Pharmacy or other appropriate State agency] becomes aware of a physician who is distributing any amount of compounded human drug products interstate, the [insert State Board of Pharmacy or other appropriate State agency] will notify the appropriate regulator of physicians within the State. The [insert State Board of Pharmacy or other appropriate State agency] will, within 30 business days of identifying a physician who is distributing any amount of compounded human drug products interstate, also notify FDA by submission to an Information Sharing Network or by email to StateMOU@fda.hhs.gov.

c. Submission and Disclosure of Information
   1. When submitting information using StateMOU@fda.hhs.gov regarding complaints relating to human drug products compounded by a pharmacy and distributed outside the State, or regarding distribution of inordinate amounts of human drug products compounded by a pharmacy interstate, the following minimum information will be included. Note, this information can be submitted to an Information Sharing Network for sharing with FDA.

   a. Complaints:
      i. Name and contact information of the complainant, if available;
      ii. Name and address of the pharmacy that is the subject of the complaint;
      iii. Description of the complaint, including a description of any compounded human drug product that is the subject of the complaint;
      iv. [Insert State Board of Pharmacy or other appropriate State agency]’s assessment of whether the complaint was substantiated, if available; and
      v. Description and date of any actions the [insert State Board of Pharmacy or other appropriate State agency] has taken to address the complaint.

   b. Inordinate Amounts:
i. Name and address of the pharmacy that distributed inordinate amounts of compounded human drug products interstate;

ii. The number of prescription orders for compounded human drug products that the pharmacy sent out of (or caused to be sent out of) the facility in which the drug products were compounded during that same calendar year;

iii. The number of prescription orders for compounded human drug products that were dispensed (e.g., picked up by a patient) at the facility in which they were compounded during that same calendar year;

iv. The total number of prescription orders for compounded human drug products distributed interstate during that same calendar year;

v. The total number of prescription orders for sterile compounded human drug products distributed interstate during that same calendar year;

vi. The names of States in which the pharmacy is licensed and the names of States into which the pharmacy distributed compounded human drug products during that same calendar year; and

vii. Whether the [insert State Board of Pharmacy or other appropriate State agency] inspected for and found during its most recent inspection that the pharmacy distributed compounded human drug products without valid prescription orders for individually identified patients during that same calendar year.

2. When submitting information using StateMOU@fda.hhs.gov regarding complaints relating to human drug products compounded by a physician, or regarding distribution of any amount of human drug products compounded by a physician interstate, the following minimum information will be included, if available. Note, this information can be submitted to an Information Sharing Network for sharing with FDA.

   a. Name and contact information of the complainant or notifier;

   b. Name and address of the physician that is the subject of the complaint or notification; and
c. Description of the complaint or notification, including a description of any compounded human drug product that is the subject of the complaint or notification.

3. The parties to this MOU will share information consistent with applicable statutes and regulations. The parties recognize that a separate agreement under 21 CFR 20.88 may be necessary before FDA can share information that is protected from public disclosure. Such an agreement will govern FDA’s sharing of the following types of information:

- Confidential commercial information, such as information that would be protected from public disclosure under Exemption 4 of the Freedom of Information Act (FOIA) (5 U.S.C. 552(b)(4));

- Personal privacy information, such as information that would be protected from public disclosure under Exemption 6 or 7(C) of the FOIA (5 U.S.C. 552(b)(6) and(7)(C)); or

- Information that is otherwise protected from public disclosure by Federal statutes and their implementing regulations (e.g., the Trade Secrets Act (18 U.S.C. 1905), the Privacy Act (5 U.S.C. 552a), other FOIA exemptions not mentioned above (5 U.S.C. 552(b)), the Health Insurance Portability and Accountability Act (Public Law 104-191), and FDA’s regulations in parts 20 and 21 (21 CFR parts 20 and 21)).

FDA agrees that information provided to FDA by the [insert State Board of Pharmacy or other appropriate State agency] will only be disclosed consistent with applicable Federal law and regulations governing the disclosure of such information, including the FOIA (5 U.S.C. 552(b)), the FD&C Act (21 U.S.C. 301 et seq.), 21 U.S.C. 331(j), 21 U.S.C. 360j(c), the Trade Secrets Act (18 U.S.C. 1905), FDA’s regulations in 21 CFR parts 20 and 21, and other pertinent laws and regulations.

IV. ENFORCEMENT AUTHORITIES AND LEGAL STATUS OF AGREEMENT

The parties to this MOU recognize that FDA and the [insert State Board of Pharmacy or other appropriate State agency] retain the statutory and regulatory authorities provided by the FD&C Act, other Federal statutes and attendant regulations, and State statutes and regulations. The parties also recognize that this agreement does not restrict FDA or any other Federal agency from taking
enforcement action, when appropriate, to ensure compliance with Federal statutes, including the FD&C Act and attendant regulations, or prevent the [insert State Board of Pharmacy or other appropriate State agency] from taking enforcement action, as appropriate, to ensure compliance with applicable State statutes and regulations. This MOU does not create or confer any rights for or on any person. By signing this MOU, the [insert State Board of Pharmacy or other appropriate State agency] affirms that it now possesses and will maintain, at the discretion of the State legislature, the legal authority (under State statutes and/or regulations) and the resources necessary to effectively carry out all aspects of this MOU. If State law changes such that the [insert State Board of Pharmacy or other appropriate State agency] no longer has the legal authority or resources necessary to effectively carry out all aspects of this MOU, the [insert State Board of Pharmacy or other appropriate State agency] will notify FDA within 60 calendar days of the change in legal authority.

V. NAME AND ADDRESS OF PARTICIPATING AGENCIES

U.S. Food and Drug Administration
Center for Drug Evaluation and Research
Office of Compliance
Office of Unapproved Drugs and Labeling Compliance
10903 New Hampshire Avenue
Bldg. 51, Suite 5100
Silver Spring, MD 20993-0002
Telephone: (301) 796-3110
Email: StateMOU@fda.hhs.gov

[Insert State Board of Pharmacy or other appropriate State agency and its contact information]

Upon signing the MOU, each party must designate one or more liaisons to act as points of contact. Each party may designate new liaisons at any time by notifying the other party’s liaison(s) in writing. If, at any time, an individual designated as a liaison under this agreement becomes unavailable to fulfill those functions, the parties will name a new liaison within 2 weeks and notify the other party’s liaison(s).

VI. PERIOD OF AGREEMENT

a. When accepted by both parties, this MOU will be effective from the date of the last signature and will continue until terminated by either party. It may be terminated in writing by either party, upon a 60 calendar day notice of termination. Notice of termination will be sent to the address listed in section V of this MOU.
b. If the [State Board of Pharmacy or other appropriate State agency] does not adhere to the provisions of this MOU, including conducting an investigation of complaints related to compounded human drug products distributed outside the State, the MOU may be terminated upon a 60 calendar day notice of termination.

In case of termination, FDA will post a notice of the termination on its Web site and the [insert State Board of Pharmacy or other appropriate State agency] will notify all pharmacies that compound drug products in the State and notify the State authority that licenses or regulates physicians of the termination and advise them that as of 60 calendar days from the date of the posting of the termination notice, compounded human drug products may be distributed (or caused to be distributed) out of the State only “in quantities that do not exceed 5 percent of the total prescription orders dispensed or distributed” by the licensed pharmacy or physician (section 503A(b)(3)(B)(ii) of the FD&C Act).

VII. APPROVALS

<table>
<thead>
<tr>
<th>APPROVED AND ACCEPTED FOR THE U.S. FOOD AND DRUG ADMINISTRATION</th>
<th>APPROVED AND ACCEPTED FOR [insert State Board of Pharmacy or other appropriate State agency]</th>
</tr>
</thead>
<tbody>
<tr>
<td>By (Type Name)</td>
<td>By (Type Name)</td>
</tr>
<tr>
<td>Title</td>
<td>Title</td>
</tr>
<tr>
<td>Date</td>
<td>Date</td>
</tr>
</tbody>
</table>
Appendix A. Definition of Terms for the Purposes of this MOU

- **Adverse Drug Experience**: Any adverse event associated with the use of a drug in humans, whether or not considered drug related, including the following: an adverse event occurring in the course of the use of a drug product in professional practice; an adverse event occurring from drug overdose, whether accidental or intentional; an adverse event occurring from drug abuse; an adverse event occurring from drug withdrawal; and any failure of expected pharmacological action (21 CFR 310.305(b)).

- **Distribution of compounded human drug products interstate**: Means that a pharmacy or physician has sent (or caused to be sent) a compounded drug product out of the State in which the drug was compounded.

- **Information Sharing Network**: An information sharing network designated by FDA for purposes of this MOU to collect, assess, and allow review and sharing of information pursuant to this MOU.

- **Inordinate Amounts**: A pharmacy has distributed an inordinate amount of compounded human drug products interstate if the number of prescription orders for compounded human drug products that the pharmacy distributed interstate during any calendar year is greater than 50 percent of the sum of: (i) the number of prescription orders for compounded human drug products that the pharmacy sent out of (or caused to be sent out of) the facility in which the drug products were compounded during that same calendar year; plus (ii) the number of prescription orders for compounded human drug products that were dispensed (e.g., picked up by a patient) at the facility in which they were compounded during that same calendar year.9

- **Product Quality Issue**: Information concerning (1) any incident that causes the drug product or its labeling to be mistaken for, or applied to, another article; or (2) any bacteriological contamination; any significant chemical, physical, or other change or deterioration in the distributed drug product; or any failure of one or more distributed batches of the drug product to meet the applicable specifications (21 CFR 314.81(b)(1)). Contamination in general, including but not limited to mold, fungal, bacterial, or particulate contamination, is a product quality issue.

- **Serious Adverse Drug Experience**: Any adverse drug experience occurring at any dose that results in any of the following outcomes: death, a life-threatening adverse drug experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital

---

9 The definition of *inordinate amounts* in this MOU is separate and distinct from and should not be used in relation to the term *inordinate amounts* as it is used in section 503A(b)(1)(D) of the FD&C Act (pertaining to compounding a drug product that is essentially a copy of a commercially available drug product). The interpretation of this term in each instance necessarily is based on the particular context of the distinct provisions within 503A in which the term appears.
anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered a serious adverse drug experience when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse (21 CFR 310.305(b)).

- **Serious Product Quality Issue**: Any product quality issue that may have the potential to cause a serious adverse drug experience (e.g., possible contamination, superpotent product).
Pharmacist Impact on Reducing Medication Costs for Patients and Decreasing Medication Waste: Implementation and Expansion of the South Dakota Drug Repository Pilot Program

Amanda M. Kuhn, PharmD
PGY2 Health System Pharmacy Administration & Leadership Resident
Amanda.kuhn@avera.org
Avera McKennan Hospital
1325 Cliff Ave S, Sioux Falls, SD 57105
Financial Disclosure: recipient of South Dakota Society of Health-System Pharmacists Residency Grant in amount of $500

Rachel J. Elsey, PharmD, BCOP
Rachel.elsey@avera.org
Oncology Pharmacist
Avera Cancer Institute
1000 E 23rd St, Suite 220, Sioux Falls, SD 57105

Robin A. Lockhorst, PharmD, BCPS, BCOP
Oncology Pharmacy Research Coordinator
Robin.lockhorst@avera.org
Avera Cancer Institute
1000 E 23rd St, Suite 320, Sioux Falls, SD 57105
Matthew J. Toennies, PharmD, CSP

Matthew.toennies@avera.org

Pharmacy Manager

Avera Specialty Pharmacy

1301 S Cliff Ave., Suite 200, Sioux Falls, SD 57105
Pharmacist Impact on Reducing Medication Costs for Patients and Decreasing Medication Waste:

Implementation and Expansion of the South Dakota Drug Repository Pilot Program
ABSTRACT

Purpose

Data published in 2019 found 37 states had laws allowing unused medications to be donated and re-dispensed to patients through drug repository programs (DRPs). In South Dakota, this is prohibited based on rule, ARSD20:51.13:02, summarized as pharmacies are prohibited to accept unused medications from patients. A pilot program was implemented with the objective to provide evidence demonstrating the impact provided to patients.

Methods

This retrospective, chart-reviewed study analyzed patient data from the DRP and a matched cohort from July 1, 2019 to February 28, 2021. Primary objectives were to track the number of prescriptions filled and average wholesale price of each prescription dispensed through the DRP. The secondary outcome was to compare the time for patients to receive prescriptions, from time of prescribing to insurance approval.

Results

Since implementation, over $2.4 million in prescription drugs have been donated. Prescriptions have been dispensed to 135 patients, totaling over $1.3 million based on average wholesale price. In comparing the DRP to matched cohort, DRP patients waited on average 13.5 days for insurance approval while matched cohort patients waited on average two days for insurance approval. The results showed DRP patients were able to pick up their prescription on average 14.5 days prior to insurance approval – meaning they were able to start therapy with a new medication over two weeks ahead of time.

Conclusion
The DRP pilot program showed improved access to medications, decreased costs for patients, and lessened prescription drug waste. Pharmacists are critical to the success of programs by ensuring the safety and viability of donated medications. Additionally, this program promotes pharmacists optimizing overall medication access and care.

**Keywords:** drug repository, specialty pharmacy, pharmacist, medication access, waste reduction
BACKGROUND

In the United States, state boards of pharmacy are responsible for establishing rules that dictate how patients can safely and legally access medications. As of 2019, 37 states had laws allowing unused medications to be donated and redispensed to patients through drug repository programs.\textsuperscript{1, 2} Drug repository programs are driven by patient needs that have been identified by healthcare providers including patient advocates, pharmacists, nurses, and physicians, along with patient desires to give back in order to decrease the financial burden of medication for others. In January 2020, the American Society of Clinical Oncology issued a position statement on state drug repository programs, outlining their support, in that widespread use of such programs could lower costs for patients and payers and improve access to treatment for people who are unable to afford high-cost cancer drugs—all while reducing the amount of unused medications in the outpatient setting.\textsuperscript{1} Redispensing of unused medication may assist patients in need, offering timely and affordable access to medications prescribed while also lessening waste of healthcare dollars on such things as hazardous medication disposal. Drug repository programs can also provide a bridge for those patients awaiting access to medication assistance programs or prior authorizations, allowing them to start therapy immediately.

In South Dakota, returning unused medications is prohibited based on the following rule, ARSD20:51.13:02 Return of unused drugs, summarized as pharmacists and pharmacies are prohibited to accept unused drugs or prescribed medications from patients or their proxy. Noticing the need for a drug repository program in South Dakota, especially with several nearby states having functioning programs in place\textsuperscript{3, 4, 5}, oncology clinic pharmacists and specialty
pharmacists within Avera McKennan worked with the South Dakota Board of Pharmacy (SDBOP) to propose the development of a drug repository pilot program at the Avera Specialty Pharmacy (ASP). ASP was originally granted a one-year variance for ARSD20:51.13:02 to allow the pharmacy to accept the return of unused drugs and redispense the drugs under the following stipulations:

1. Only legend drugs in the original, unopened, sealed or tamper-evident container which includes lot number(s) and expiration date(s) are eligible for donation

2. Drugs packaged in single-unit doses may be accepted and dispensed if the outside packaging has been opened however the single unit-dose package is unopened

The variance was granted starting July 1, 2019 and extended for an additional year through June 30, 2021. Policies and procedures were created for accepting, storing, dispensing, and documenting donated legend drugs. The creation of patient donation and receipt forms helped to ensure transparent communication and adequate documentation of all program transactions. The policies dictated what medications would not be accepted, including controlled substances, drugs with REMS requirements, and drugs with temperature sensitive storage requirements.

The pilot program initially focused on oncology specialty medications due to the expensive nature of those medications and frequent therapy changes. During the second year of operation, the goal was to increase the specialty medication scope through increased awareness and education to employees across the rural Avera footprint, focusing on specialty disease states of rheumatology, infectious disease, and transplant/hepatology, along with greater advertisement to patients through flyers, webpage information, and television
broadcasts. Working to engage the health system outside of the Sioux Falls region to ensure patients could participate anywhere across the state, the program received a grant from the South Dakota Society of Health-System Pharmacists to assist with shipping costs of repository donations and dispensations to and from ASP.

METHODS & MATERIALS

The objective of this study was to demonstrate the impact this program aims to provide to the community in South Dakota by increasing patient access to medication.

Endpoints

The primary objective was to track the number of prescriptions filled and the average wholesale price of each prescription for patients who received medication through the drug repository program. Secondary objectives included comparing the amount of time it takes for a patient to start a medication, from time of prescribing to insurance approval, between drug repository dispensations and a matched cohort group, and to identify potential cost to pharmacies that participate in such a program including time spent counseling patients, maintaining inventory, and providing community awareness of the program.

Inclusion/Exclusion Criteria

The study population inclusion criteria for the drug repository program patient group included dispensations from the ASP drug repository; the inclusion criteria for the matched cohort group included dispensations filled outside of ASP drug repository program, a new prescription for the same medication as the drug repository program patient, and the medication being dispensed within a 12 month period around the drug repository program
dispensation. The only exclusion criteria was prescriptions filled outside of the study timeframe of July 1, 2019 to February 28, 2021.

**Study Design**

This retrospective, chart-reviewed study analyzed patients from the DRP and a matched cohort patient group from July 1, 2019 to February 28, 2021 to compare the time for patients to receive prescriptions. Electronic medical records, including MOSAIQ, Meditech, EnterpriseRx, and Dromos, were utilized in order to collect the patient information listed:

- Patient name
- Prescription number
- Medication prescribed
- Quantity prescribed
- Prescription benefit coverage
- Prescription benefit utilized (for matched cohort patients only)
- Date prescription written
- Date prescription filled
- Date of drug receipt by patient (pickup or mailed date)
- Date of insurance approval (if applicable)
- Cost of prescription filled based on AWP (for drug repository patients only)

With the secondary endpoint of potential cost to pharmacies, self-reported data was collected regarding time spent:

- Writing policies, protocols, and creating forms
- Training staff
• Counseling patients about utilizing the drug repository program
• Maintaining donation inventory
• Developing community outreach and awareness of the program
• Coordinating and creating internal webpage with all inventory data

RESULTS

Since implementation of the program through mid-June 2021, 141 prescriptions have been dispensed from the repository totaling $1,397,955.64 based on average wholesale price. The average cost of each prescription dispensed amounts to around $10,000. During this time, $2,514,571.54 in medications have been donated to the repository program. Some of the most commonly donated and dispensed medications can be found in Table 1.

Regarding the secondary endpoint of comparing the amount of time it takes for a patient to start a medication, from time of prescribing to insurance approval, between drug repository dispensations and a matched cohort group, 68 dispensations in the drug repository group were able to be matched to 55 dispensations in the cohort patient group. For the drug repository group, 13 dispensations were excluded as the date of insurance approval was before the written date of the prescription, meaning it was not the first time the patient had received the medication. Of the 55 dispensations reviewed for inclusion criteria, 28 of them had an insurance approval date after the prescription written date, with the average difference in wait time for insurance approval around 13.5 days. For 16 of those 28 dispensations, the patient picked up or was mailed medication from the drug repository program on average 14.5 days prior to their insurance approval – meaning they were able to start therapy with a new
medication over two weeks ahead of time. For the additional 27 dispensations included, insurance approval was not necessarily a factor in why they received medication from the repository. It was due to other reasons including a lapse in coverage, a delay in the ability for the patient to obtain their medication or supply, or the prescription being a medication not routinely covered by insurance, meaning it saved the patient an out-of-pocket expense.

When comparing to the matched cohort group of patients, of the 55 dispensations, eight of them were excluded as insurance approval was before the written date of the prescription, meaning it was not the first fill by the patient. Forty-seven dispensations met inclusion criteria where the insurance approval was after the prescription written date, with the average difference in wait time for insurance approval around two days. While this time was much shorter than our average wait time for the repository program patients, it means we are identifying those patients who would benefit most from the repository, rather than those patients with less concern over coverage or paying for medication.

The additional secondary endpoint was focused on potential program cost. Initially, the time to set up the program including writing policies, protocols, and creating forms, training staff and the creation of an internal inventory webpage amounted to 15 hours of pharmacist time. The overall maintenance of the program after two years amounts to one and a half to two hours of pharmacist time per week.

**DISCUSSION**

**Strengths**
The program has been able to demonstrate significant cost savings through repurposing of medication that would have otherwise been destroyed. The strengths of this study were the ability to show the drug repository pilot program can provide medication to patients over two weeks ahead of time, while waiting for insurance and/or prior authorization approval, and provided data highlighting the help provided to patients for lapses in coverage and delays in obtaining medications or supplies – a huge part of the mission of the Avera Health organization.

Limitations

The limitations of this study included a small patient sample for the repository and matched cohort comparison, and with data requiring manual chart review making it challenging to uncover insurance information and coverage dates at times.

CONCLUSION

Drug repository programs have been shown to improve access to medications, decrease costs for patients, and lessen prescription drug waste. Pharmacists are critical to the success of programs by ensuring the safety and viability of donated medications, along with dispensing and counseling of patients on their medications. For patients waiting on insurance approval, based on our study results, they were able to receive medication from the repository program on average over 14 days ahead of time. Current time spent maintaining program donations and dispensations amounts to around one and a half to two hours per week. This drug repository pilot program not only helps to assist patients in South Dakota, it promotes pharmacists optimizing overall medication access and care.
REFERENCES


TABLES AND FIGURES

Table 1. Medications Most Commonly Donated and Dispensed

<table>
<thead>
<tr>
<th>Medications Most Commonly Donated and Dispensed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abemaciclib 100 mg &amp; 150 mg tablets</td>
</tr>
<tr>
<td>Abiraterone 250 mg tablet</td>
</tr>
<tr>
<td>Alpelisib 300 mg (2x150 mg) dose</td>
</tr>
<tr>
<td>Apixaban 5 mg tablet</td>
</tr>
<tr>
<td>Dasatinib 100 mg tablet</td>
</tr>
<tr>
<td>Enoxaparin 100 mg/1ml syringe</td>
</tr>
<tr>
<td>Everolimus 5 mg tablet</td>
</tr>
<tr>
<td>Heparin Lock Flush (100 units/mL) 3 mL</td>
</tr>
<tr>
<td>Ibrutinib 560 mg tablet</td>
</tr>
<tr>
<td>Olaparib 150 mg tablet</td>
</tr>
<tr>
<td>Upadacitinib 15 mg tablet</td>
</tr>
</tbody>
</table>

Figure 1. Number of Donations and Dispensations

![Graph showing the number of donations and dispensations over time in the South Dakota Drug Repository Program](image-url)
BOARD POLICY STATEMENT COVID-19 TESTING BY PHARMACISTS

The South Dakota Board of Pharmacy acknowledges that the United States Department of Health and Human Services (HHS) published guidance on April 8, 2020 regarding the fact that the Public Readiness and Emergency Preparedness (PREP) Act passed, authorizing licensed pharmacists to order and administer COVID-19 tests, including serology tests, and that the Food and Drug Administration (FDA) has authorized through its Emergency Use Authorization (EUA.) Further the HHS Office of General Counsel has issued an advisory opinion that says licensed pharmacists may order and administer COVID-19 tests regardless of state or local restrictions.

Further, the Coronavirus Aid, Relief, and Economic Security (CARES) Act allows patients who are uninsured to be billed by pharmacists to HRSA for COVID-19 testing services. Additionally, the SD Medicaid program will pay pharmacists as well.

It is the Board’s policy that during the COVID-19 Federal Emergency, pharmacists may order, perform, and report COVID-19 tests without a separate provider order or collaborative practice agreement if the requirements listed below are met. Currently, most of the tests are Clinical Laboratory Improvement Amendments (CLIA) waived tests per the Centers for Disease Control (CDC) and supported by the Food and Drug Administration (FDA) and therefore will require a CLIA waiver to perform these tests. When the emergency declaration has ended, the pharmacist may only perform these tests by physician order. This policy statement is to further clarify and allow pharmacists to order and perform COVID-19 testing for their patients.

This policy is in effect for the duration of the State of South Dakota declared emergency or the PREP Act, whichever expires soonest for countermeasures against COVID-19 concludes.

Before a pharmacist may begin testing, the following must be completed:

1. The pharmacy notifies the Board before testing commences and provides the Board with the policy and procedures written for testing which includes the type of FDA authorized test, staff training, the location of testing, i.e., parking lot of pharmacy, planned personal protective equipment (PPE) use, documentation, informing the provider of the test results.
2. A pharmacist conducting COVID-19 testing must be dedicated to testing only and may not be working in a dispensing role while performing testing. Pharmacy interns and technicians may assist in the COVID-19 testing if the actual testing is performed by a patient or a pharmacist.
3. For testing that is completed by the patient, pharmacy staff may provide the patient with supplies and education. Pharmacy technicians and interns may witness the patient performing self-testing and proper placement of the test medium into proper containers, if applicable.
4. The pharmacy must obtain a Clinical Laboratories Improvement Act (CLIA) waiver to perform tests, if they will be using a device to process the tests in house. If sending to a commercial laboratory, the CLIA waiver is not required.

5. The pharmacy must assure that all staff performing and assisting with these tests have consented to performing the assigned tasks, have accessible the appropriate PPE to protect themselves and any staff from aerosolization, and have received proper training to perform the assigned tasks involved in the testing process.

6. The pharmacist may perform testing in a location which is not a licensed location, if the pharmacist is conducting the testing is licensed with the Board.

7. The pharmacist or testing vendor must report test results to the South Dakota Health Department at sd.gov/diseasereport

8. The pharmacy must receive an approval from the board allowing the pharmacy to begin testing before any type of testing is done in the pharmacy or by pharmacy staff.

9. For PREP Act Immunization Guidance, see Policy Statement 20-12-11

References:


2. FDA Emergency Use Authorization for therapeutic and medical devices to diagnose and respond to public health emergencies: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations


4. HRSA Uninsured CARES Act: COVID-19 Uninsured Program Portal


Passed by the South Dakota Board of Pharmacy on June 5, 2020.

Revised and Passed by the South Dakota Board of Pharmacy on September 24, 2020

Revised and Passed by the South Dakota Board of Pharmacy on June 25, 2021
DATE: December 3, 2010, Revised June 25, 2021

WHAT: Board Policy Statement Number 10-12-01

WHY: GUIDELINES FOR APPROVAL OF PHARMACISTS OR OTHER PHARMACY EMPLOYEES WORKING AT HOME

INTRODUCTION

The Board requires pharmacies that allow pharmacists and other employees to perform routine pharmacy functions from home to have policies and procedures in place that ensure compliance with good practice standards. This is necessary to ensure that patient safety and security of the patient's health information is maintained at the same level as if those functions were performed within the pharmacy.

GUIDELINES

A copy of the policies and procedures for working at home must be readily available at the pharmacy for review by the Board of Pharmacy Inspector. Home based workers shall also have a copy at their home work site.

The Policies and Procedures shall include the following:

1. Home based workers must be assigned a Virtual Personal Network (VPN) and a secure log in to log in to remote systems. a secure log in to the system via a Virtual Personal Network (VPN) or terminal server with two-factor identification.

2. Home based workers must maintain a business telephone line.

1. Home based workers must maintain a separate designated area at home for work. This includes a locking desk or file cabinet.

2. Home based workers must take precautions to protect information from theft.

3. Home based workers must collect, use, and disclose information only for the purpose associated with their job role and function.

4. Home based workers must have access to clinical resources as designated by the board.

5. Home based workers must have a means of disposal of protected health information (PHI) that will not risk the security of that information.
6. All pharmacy technicians and interns working remotely must have direct communication access to a pharmacist and the pharmacist is able to supervise the technician and interns electronically.

Passed by the South Dakota Board of Pharmacy on 12/03/2010
Revised and Passed by the South Dakota Board of Pharmacy June 25, 2021
May 21, 2021

Via Email

South Dakota State Board of Pharmacy
Attention: Kari Shanard-Koenders
Executive Director
4001 W. Valhalla Blvd., Suite 106
Sioux Falls, SD 57106
Email: kari.shanard-koenders@state.sd.us

Dear Executive Director Shanard-Koenders and South Dakota Board of Pharmacy Members,

On behalf of all pharmacies owned and operated by Walgreen Co. in the state South Dakota, I am writing to request appearance at your June 25, 2021 meeting to discuss our pilot project expanding the role of technician immunization administration to all ACIP approved vaccines.

Community pharmacy-based immunizations have been one of the most significant achievements in public health in recent years. Various studies have demonstrated that pharmacists increase vaccination rates against influenza, pneumonia, and herpes zoster. Patients have shown high acceptance of pharmacy-based immunizations, with 97% of vaccinated patients’ surveyed reporting satisfaction with their experience in the pharmacy. One-third of all influenza vaccines given during the 2013-2014 flu season were provided in a community pharmacy. In addition, studies have demonstrated that pharmacy-based immunizations are more cost-effective than those provided in other settings, including physician offices.1

Community pharmacies have further demonstrated their value in public health through partnerships with the Centers for Disease Control and Prevention and the U.S. Department of Health and Human Services to deliver COVID-19 testing and vaccinations to optimize supply and equity during the pandemic. Further, HHS has taken steps to ensure that pharmacies and pharmacists are optimized to their fullest capacity through the technician vaccine administration allowances in the PREP Act.2 Most recently, the CDC and ACIP issued interim clinical considerations and recommendations for the co-administration of other routine vaccinations with the COVID-19 vaccine to expand vaccination rates further.3 While the U.S. Department of Health and Human Services Healthy People goals for 2030 include increasing vaccination rates for the flu vaccine and Tdap during pregnancy, neither of these vaccines are covered within the scope and authority within the PREP Act.4 Our proposed pilot program would address the need for co-administration of vaccines outside of the scope of the PREP act to increase the vaccination rates for other routine vaccines for South Dakotans. Enabling trained and supervised technicians to administer all ACIP recommended vaccines allows the Pharmacist to focus their time and efforts on the clinical evaluation of gaps in care and consultation to improve vaccination rates safely and efficiently.

We are requesting approval of the pilot for one year with a six-month check in on results.

If the Board would like additional information, please feel free to contact me.

Sincerely,

Lorri Walmsley, R.Ph.

Enclosure: Walgreens South Dakota Technician-Administered Immunization Program Pilot
Walgreens South Dakota Technician-Administered Immunization Program Pilot

Introduction
Community pharmacy-based immunizations have been one of the most significant achievements in public health in recent years. Various studies have demonstrated that pharmacists increase vaccination rates against influenza, pneumonia, and herpes zoster. Patients have shown high acceptance of pharmacy-based immunizations, with 97% of vaccinated patients surveyed reporting satisfaction with their experience in the pharmacy. One-third of all influenza vaccines given during the 2013-2014 flu season were provided in a community pharmacy. In addition, studies have demonstrated that pharmacy-based immunizations are more cost-effective than those provided in other settings, including physician offices.1

Community pharmacies have further demonstrated their value in public health through partnerships with the Centers for Disease Control and Prevention and the U.S. Department of Health and Human Services to deliver COVID-19 testing and vaccinations to optimize supply and equity during the pandemic. Further, HHS has taken steps to ensure that pharmacies and pharmacists are optimized to their fullest capacity through the technician vaccine administration allowances in the PREP Act. 2 Most recently, the CDC and ACIP issued interim clinical considerations and recommendations for the co-administration of other routine vaccinations with the COVID-19 vaccine to expand vaccination rates further. 3 While the U.S. Department of Health and Human Services Healthy People goals for 2030 include increasing vaccination rates for the flu vaccine and Tdap during pregnancy, neither of these vaccines are covered within the scope and authority within the PREP Act.4 Our proposed pilot program would address the need for co-administration of vaccines outside of the scope of the PREP act to increase the vaccination rates for other routine vaccines for South Dakotans. Enabling trained and supervised technicians to administer all ACIP recommended vaccines allows the Pharmacist to focus their time and efforts on the clinical evaluation of gaps in care and consultation to improve vaccination rates safely and efficiently.

Goals
The goals of our program are threefold, first and foremost, to safely improve vaccination rates for all ACIP recommended vaccines for South Dakotans. Second, enhance pharmacy workflow and patient experience by offering a seamless experience for patients who wish to receive multiple vaccinations recommended by ACIP and the CDC. And lastly, to improve pharmacy team member satisfaction and engagement through expanded roles and optimization of workflow.

Objectives
The program will achieve its goals by allowing Certified Immunization Trained Technicians to perform all ACIP recommended vaccines for patients in our 14 South Dakota-based locations. All participating technicians will be supervised by an Immunization Trained Pharmacists and will opt into vaccination after receiving the training as outlined in the program details below and demonstrated proficiency. Immunization Trained technicians will only participate in the non-clinical portions of the vaccine administration, and vaccines will only be given after the clinical assessment and counseling on potential risks and side effects on all immunization is performed by the Immunization Trained Pharmacist.
Walgreens South Dakota Technician-Administered Immunization Program Pilot

Program Details

**Employee Selection:**
South Dakota Licensed and Certified Pharmacy Technicians that have opted into participation, have completed immunization administration training, and have demonstrated proficiency.

**Training:**
Select Certified Pharmacy Technicians will complete training as outlined below:

<table>
<thead>
<tr>
<th>Activity</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>APHA Pharmacy-Based Immunization Administration by Pharmacy Technicians Training Program</td>
<td>Self-Study Learning - 2 hours self-study with assessment</td>
</tr>
<tr>
<td>Adult &amp; Child CPR for Healthcare Providers [Cardio Partners only] OR Adult, Child, and Infant First Aid/CPR/AED Online</td>
<td>Blended Online and Live training OR Online training</td>
</tr>
<tr>
<td>OSHA Bloodborne Pathogen Training (BBP)</td>
<td>Online Training in LTMP Final Assessment - Completed Annually</td>
</tr>
<tr>
<td>Immunization Administration Training</td>
<td>Overview and acknowledgment of vaccine preparation and administration procedures for all immunizations</td>
</tr>
<tr>
<td>Training &amp; Authorization Form</td>
<td>Training with the pharmacy manager to demonstrate mastery of administration</td>
</tr>
</tbody>
</table>

Documentation of training activities will be maintained by employee in file #17 in the pharmacy and the Walgreens Learning and Talent Management Portal (LTMP.)

**Description of Immunization Pharmacy Technician Functions:**

1. Enter the Vaccine into the Immunization Selection Tool and Intercom Plus
2. Technician chooses the appropriate vaccine administration record (VAR); flu, non-flu, offsite clinic
3. Gather immunization, emergency supplies, and prepare the vaccine.
   - Sharps Container, Emergency Supply Kit, gloves, alcohol pads, bandages, and cotton balls
   - Reconstitute vaccine if applicable and prepare the appropriate dose for administration
Walgreens South Dakota Technician-Administered Immunization Program Pilot

4. Administer Vaccine:
   - Inside the immunization area/consultation room, to area technician will question and confirm with the patient:
     i. Full Name
     ii. Date of Birth
     iii. Vaccination
   - Complete immunization using good hand hygiene and appropriate immunization technique.
   - Complete the chart in Section F
   - Instruct the patient to remain in the area for approximately 15 minutes for observation to monitor the patient for post-immunization adverse reactions.

5. Pharmacist and Technician will complete post-immunization requirements.
   - Technician will clearly print name and Pharmacist clearly print and sign Section F of the VAR
   - Technician will scan the VAR into the patient profile in Intercom Plus

The Pharmacist will be responsible for the clinical assessment and counseling on the vaccination, including potential risks and side effects on all immunizations.

Procedures for Ensuring Public Health and Safety

Immunization-trained Pharmacy Technicians will only participate in the non-clinical functions of vaccine administration. The Pharmacist will be responsible for the clinical assessment and counseling on the vaccination, including potential risks and side effects on all immunizations.

1. Clinical Review
   Upon entry of the vaccination into Intercom Plus, the Immunization Trained Pharmacist will perform the clinical review to assess the appropriateness of therapy, review the statewide immunization registry, screen for contraindications/precautions, and perform vaccine verification. If a contraindication or precaution is present, the patient’s primary healthcare provider will be consulted, or a referral to care will be advised.

2. Consultation
   Before vaccine administration, the patient will be counseled regarding the potential risks, side effects of all immunizations and a discussion about potential gaps in care to include recommendations for other vaccinations. The VIS will be provided and reviewed before administration with the patient or the patient’s parent/legal guardian.

3. Informed Consent
   The Pharmacist will screen patients for receipt of the vaccine based upon ACIP Guidelines. No qualified patient shall receive a Vaccine who fails to meet the stated criteria, has a medical contraindication to the vaccine, an allergy to
Walgreens South Dakota Technician-Administered Immunization Program Pilot

components of the vaccine, or severe prior reaction to a Vaccine. Each Pharmacist will inform the Vaccine recipient of the potential benefits and risks of the vaccine. This disclosure must be documented by the execution of informed consent by each qualified individual/patient (or the qualified individual/patient’s parent or legal guardian in the event the qualified individual/patient is less than eighteen (18) years of age) receiving a Vaccine.

4. **Vaccines**

   All vaccines indicated in our South Dakota Standing Order Protocol are recommended and follow current published CDC and ACIP recommendation guidelines and recommended schedules and COVID-19 vaccines as recommended and approved by ACIP.

5. **Post Administration**

   Following administration of a Vaccine, a Pharmacy Provider will recommend qualified individuals/patients remain under observation for at least fifteen (15) minutes, following state and local regulations, to monitor for adverse events. A Pharmacy Provider will instruct the qualified individual/patient to report any adverse events to the Pharmacy Provider after receiving the vaccine.

6. **Waste Disposal.**

   Sharps and syringes will be disposed of in an approved impenetrable sharps container using universal precautions. All full sharps containers must be disposed of according to state regulations.

7. **Patient Record.**

   Each vaccine will be documented in Intercom Plus and an electronic record of each patient for five (5) years or required Law. Such record shall include: the name, address, and date of birth of the patient; the date of administration and site of injections; the name, dose, manufacturer’s lot number, and expiration date of the vaccine; name and address of the patient’s primary health care provider (“PCP”), as identified by the patient; the name of the Pharmacist administering the immunization; a record of any consultation or other professional information provided to the patient; and the name and date of the Vaccine Information Sheet provided to the patient. A personal immunization record card will be given to each qualified individual/patient with a record of the date of vaccination and the name/location/telephone number of the administering pharmacy.

8. **Adverse Reaction Reporting.**

   All adverse reactions to the vaccine shall be submitted to the FDA and the CDC via the Vaccine Adverse Events Reporting System (“VAERS”) form with a copy of each such report provided to the qualified individual/patient’s primary care physician.

9. **Emergency Treatment Procedures**

   In an anaphylactic reaction, the Pharmacist will follow the Walgreens Standard Operating Procedures and Emergency Procedures outlined in our South Dakota Standing Order Protocol.
Walgreens South Dakota Technician-Administered Immunization Program Pilot

10. **Workplace Safety**

All immunization Trained employees complete training on bloodborne pathogens and needlestick prevention annually. Additionally, all employees will review the Walgreens Immunization Safety playbook that provides the latest information on safety guidelines and best practices for infection control. Current safety measures include CDC immunization guidance, patient screening tools, temperature checks, facemasks and shields, hand-hygiene and cleaning procedures, and patient safety guidelines.

11. **State Registry Reporting**

All vaccines will be reported to the South Dakota Department of Health’s Vaccine Registry as required by state law.

**Rule Variance Request**

Walgreens is requesting that the South Dakota Board of Pharmacy provide a one-year variance to 20:51:28:02.01, 20:51:29:20, and 20:51:29:21(6) to allow Certified Immunization-Trained Pharmacy Technicians under the supervision of an Immunization Trained Pharmacist to administer all ACIP recommended vaccines, including COVID-19 vaccines.

Pharmacies play an integral role in the vaccination of the public that was further heightened by the COVID-19 pandemic. Properly trained and supervised Pharmacy Technicians are well suited to assist pharmacists and pharmacies with the non-clinical portions of vaccine administration, allowing pharmacists more time to identify gaps in care, counsel patients, and improve patient outcomes.

**Additional Supporting Information**

Idaho was the first adopter of this concept in 2016-17; since then, Colorado, Illinois, Indiana, Nevada, Rhode Island, Utah, and Washington have taken steps to allow this activity with several additional states discussion. Between August 1, 2019, and April 20, 2020, technicians have provided an estimated 27,000 immunizations at Walgreens pharmacies in Idaho and 19,000 immunizations in Rhode Island. The Idaho Board of Pharmacy estimated that Pharmacy Technicians gave 25,000 vaccines in the first year after adopting the rule with no adverse event or errors reported to the Board of Pharmacy.

Internal surveys have provided positive feedback on Technicians administered immunizations by pharmacists, technicians, and patients. The ability to delegate this administrative task to trained technicians allows for increased pharmacist capacity for engaging in additional clinical and patient care services.

**Technician Immunization Program Feedback and Benefits**:
- Pharmacists in the study felt that their immunizing technicians were properly trained to administer immunizations, capable of giving immunizations, and empowered by their new role within the pharmacy.
- Findings also included a pharmacist-perceived increase in vaccination rates and recommendation for other technicians to be trained to administer immunizations.
- Pharmacists’ opinions revealed that working with newly trained immunizing pharmacy technicians has not only positively affected the morale of their team, but can help to increase the number of vaccinations given by the pharmacy.
- There was no risk to pharmacist employment position as the Pharmacist must complete clinical review prior to technician administration to confirm vaccine eligibility and is responsible to confirm correct product and dosage is being provide by Technician.
Walgreens South Dakota Technician-Administered Immunization Program Pilot

- Providing technician the ability to complete the non-clinical task of immunization administration provides the pharmacist additional capacity to practice at the top of their licensure to engage patients in additional activities such as medication therapy management services, adherence monitoring, prescriptive authority, etc.

The American Pharmacist Association (APhA) House of Delegates, representing over 60,000 pharmacists nationwide supports this concept. Most recently a policy was introduced and adopted as a policy statement regarding Pharmacy Technicians Role in Immunization Administration at the 2020 Annual Meeting.8

1. APhA urges state boards of pharmacy and state legislative bodies to authorize immunization administration by qualified pharmacy technicians as a technical function that may be delegated by immunizing pharmacists.
2. APhA supports the development of standardized training in immunization administration and continuing education opportunities for immunizing pharmacy technicians.
3. APhA supports pharmacists individual discretion in delegating immunization administration to qualified pharmacy technicians with the requisite education, training, and experience.
4. APhA supports voluntary participation by pharmacy technicians in the training and provision of immunization administration
5. APhA supports the role of pharmacists as the healthcare professional providing clinical patient assessment, decision making, and patient counseling for all immunizations administered by a pharmacy technician.

References:

Walgreens South Dakota Technician-Administered Immunization Program Pilot


Pharmacy Locations

<table>
<thead>
<tr>
<th>Location #</th>
<th>Address</th>
<th>City</th>
<th>County</th>
<th>State</th>
<th>Zip</th>
<th>License Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>1975</td>
<td>1720 S SYCAMORE AVE</td>
<td>SIOUX FALLS</td>
<td>MINNEHAHA</td>
<td>SD</td>
<td>57110</td>
<td>100-1863</td>
</tr>
<tr>
<td>5242</td>
<td>4900 S CLIFF AVE</td>
<td>SIOUX FALLS</td>
<td>LINCOLN</td>
<td>SD</td>
<td>57108</td>
<td>100-1802</td>
</tr>
<tr>
<td>5243</td>
<td>2605 W 12TH ST</td>
<td>SIOUX FALLS</td>
<td>MINNEHAHA</td>
<td>SD</td>
<td>57104</td>
<td>100-1803</td>
</tr>
<tr>
<td>5514</td>
<td>1806 S MINNESOTA AVE</td>
<td>SIOUX FALLS</td>
<td>MINNEHAHA</td>
<td>SD</td>
<td>57105</td>
<td>100-1846</td>
</tr>
<tr>
<td>5643</td>
<td>540 MOUNTAIN VIEW RD</td>
<td>RAPID CITY</td>
<td>PENNINGTON</td>
<td>SD</td>
<td>57702</td>
<td>100-1813</td>
</tr>
<tr>
<td>5745</td>
<td>3620 W 41ST ST</td>
<td>SIOUX FALLS</td>
<td>MINNEHAHA</td>
<td>SD</td>
<td>57106</td>
<td>100-1810</td>
</tr>
<tr>
<td>9512</td>
<td>1125 N LACROSSE ST</td>
<td>RAPID CITY</td>
<td>PENNINGTON</td>
<td>SD</td>
<td>57701</td>
<td>100-1918</td>
</tr>
<tr>
<td>9806</td>
<td>2020 BROADWAY AVE</td>
<td>YANKTON</td>
<td>YANKTON</td>
<td>SD</td>
<td>57078</td>
<td>100-1898</td>
</tr>
<tr>
<td>10007</td>
<td>421 9TH AVE SE</td>
<td>WATERTOWN</td>
<td>CODINGTON</td>
<td>SD</td>
<td>57201</td>
<td>100-1895</td>
</tr>
<tr>
<td>10347</td>
<td>901 S BURR ST</td>
<td>MITCHELL</td>
<td>DAVISON</td>
<td>SD</td>
<td>57301</td>
<td>100-1911</td>
</tr>
<tr>
<td>10572</td>
<td>100 E SIOUX AVE</td>
<td>PIERRE</td>
<td>HUGHES</td>
<td>SD</td>
<td>57501</td>
<td>100-1920</td>
</tr>
<tr>
<td>10656</td>
<td>1902 MOUNT RUSHMORE RD</td>
<td>RAPID CITY</td>
<td>PENNINGTON</td>
<td>SD</td>
<td>57701</td>
<td>100-1927</td>
</tr>
<tr>
<td>10729</td>
<td>7120 W 41ST ST</td>
<td>SIOUX FALLS</td>
<td>MINNEHAHA</td>
<td>SD</td>
<td>57106</td>
<td>100-1925</td>
</tr>
<tr>
<td>12906</td>
<td>1430 NORTH AVE</td>
<td>SPEARFISH</td>
<td>LAWRENCE</td>
<td>SD</td>
<td>57783</td>
<td>100-1942</td>
</tr>
</tbody>
</table>
## Referrals to AMCK Hospital@Home Program

### This Program Is for:
- Medicare patients **ONLY** who meet the following requirements:

#### Social Inclusion Criteria:
- Resident within Sioux Falls City Limits
- Capacity to Consent, or has proxy who can consent
- Can identify caregiver who can agree to stay with patient for first 24 hours, and as needed after that. Caregiver must be competent to call care team. This criteria may be waived for certain patients in the discretion of the provider and patient consent

#### Social Exclusion Criteria:
- Homeless
- Unsafe or inappropriate home
- No working heat (October – April)
- In police custody
- On methadone requiring daily pickup
- Resides in facility providing on-site medical care (Skilled nursing facility)
- Domestic Violence Screen Positive
- Any positive suicide screen (PHQ-9 >20 or PSS-3 is negative)
- Other social concerns (decreased access to food, no running water)

#### Clinical Inclusion Criteria:
- 18 years of age or older
- Primary or possible diagnosis of:
  - Cellulitis / soft tissue infection
  - Heart Failure
  - Complicated UTI
  - Pneumonia
  - COPD/Asthma Exacerbation
  - Malignant Pain
  - Gout Flare
  - Diabetes complications (aka foot ulcer)
  - Anticoagulation Needs (i.e. VTE)
  - Medication Management requiring admission needs (i.e. end of life)
- Additional patients will be reviewed on a case-by-case basis and assessed based on severity of illness

#### Clinical Exclusion Criteria:
- Need for intensive care admission or telemetry
- Acute delirium, psychiatrically unstable
- Active Drug Abuse
- Pregnant or Lactating
- Dependent on Renal replacement therapy
- Arterial pH < 7.3 or >7.55
- Cannot establish peripheral access in ER
- Secondary condition: acute conditions
- Increased likelihood of transfer to Intensive Care for severe complications
- New Oxygen requirements > 3L per minute flow
- Uncorrectable hypoxemia (PO2<60 or O2 saturation <90% on > 4 L pm despite initial treatment)

### This Program Is Not for:

#### Clinical Inclusion Criteria:
- 18 years of age or older
- Primary or possible diagnosis of:
  - Cellulitis / soft tissue infection
  - Heart Failure
  - Complicated UTI
  - Pneumonia
  - COPD/Asthma Exacerbation
  - Malignant Pain
  - Gout Flare
  - Diabetes complications (aka foot ulcer)
  - Anticoagulation Needs (i.e. VTE)
  - Medication Management requiring admission needs (i.e. end of life)
- Additional patients will be reviewed on a case-by-case basis and assessed based on severity of illness

#### Clinical Exclusion Criteria:
- Need for intensive care admission or telemetry
- Acute delirium, psychiatrically unstable
- Active Drug Abuse
- Pregnant or Lactating
- Dependent on Renal replacement therapy
- Arterial pH < 7.3 or >7.55
- Cannot establish peripheral access in ER
- Secondary condition: acute conditions
- Increased likelihood of transfer to Intensive Care for severe complications
- New Oxygen requirements > 3L per minute flow
- Uncorrectable hypoxemia (PO2<60 or O2 saturation <90% on > 4 L pm despite initial treatment)

---

*These are general criteria recommendations only, and patients can be accepted on a case-by-case basis dependent on provider discretion and patient consent.*
Virtual Verification

Lauren Paul, PharmD, MS
Senior Director, Pharmacy Regulatory Affairs

June 25, 2021
What is Virtual Verification?

Virtual Verification is a process developed by CVS Health to streamline the process of filling prescriptions.

Through the Virtual Verification process, the pharmacist verifies the prescription through photographic images of the prescription taken by the licensed pharmacy technician in lieu of physically handling the prescription.

All other aspects of the prescription-filling process remain unchanged.
What are the benefits of Virtual Verification?

- **Implements patient satisfaction.**
- **Elevates the role of the registered pharmacist.**
- **Increases accountability and quality.**
Elevating the role of pharmacists
Despite a growing need for increased access to patient care services, community pharmacists spend only 21% of their professional time performing patient care services that are not associated with dispensing prescriptions.¹

To further enhance and optimize patient care services delivered at community pharmacies, leveraging trained pharmacy technicians to take on roles that have proven to not require the professional judgment of a pharmacist should be considered. Paramount and centric to all rules, including pharmacy technician roles and responsibilities, is patient safety.

Increasing the scope of pharmacy technician practice to include administrative and supportive tasks for pharmacist-provided patient care services will allow pharmacists to more effectively and efficiently provide for patients’ medication-related needs.²


In today’s workflow, physical handling consumes a majority of the pharmacist’s time during Product Verification.

1. Retrieve basket
2. Remove label and product from basket
3. Scan label
4. Scan product label
5. Open vial
6. Pour contents into Visual Verification Tray
7. **Inspect product compared to stock image**
8. Pour contents back into vial
9. Close vial
10. Retrieve empty prescription bag
11. Place contents into bag
12. Affix label to bag
13. Staple label to bag
14. Place bag into holding area

Roughly 90% of the Product Verification process is spent physically handling the product and performing manual tasks.
Virtual Verification brings physical workstation changes

Workflow:

- **DATA ENTRY**
- **DATA ENTRY VERIFICATION**
- **PRODUCTION**
- **PRODUCT VERIFICATION**
- **POS**

Hard Copy

![Hard Copy Image]

eRX

![eRX Image]
WHAT’S CHANGING?

At Production

• Technicians will take pictures of the product at production

• Technicians will bag prescriptions

• Each Production workstation will be rearranged to accommodate the Rx Imager and newly designed counting and imaging tray, prescription bags and staplers

At Product Verification

• Pharmacists will initiate product verification from the queue instead of by label scan

• Pharmacists will perform product verification from the image captured at production from anywhere

• Pharmacists will no longer bag prescriptions
So how does it work?

**RxImager Device and Counting Tray**

- Take pictures of medications only.
- Take a picture of the entire dispensed quantity. The Pharmacist will need to inspect all the pills/each product, like they do during manual verification.
- Ensure the following before taking a picture:
  - The imaging tray is fully inserted into the Rx Imager
  - Pills are not overlapping or stacked on top of one another
  - The product and/or camera is not moving
  - The front door is closed
- Use the external camera to take pictures of liquids or products that do not easily fit under the internal camera.
Processing a Prescription

The technician must fulfill a Nexium prescription for Jonathon Smith

Workflow Steps:

1. **Access Production Queue**

2. **Print Label and retrieve from inventory just as you currently do**

3. **Scan NDC to initiate three-step Accuracy Scan**
   - Keep only one script at the production station at a time
Processing a Prescription

Workflow Steps:

1. Pour pills on the elevated side of the tray
2. Count amount and slide pills to lower half of tray
3. Slide tray into the device
4. Press [Enter] once
   - Be careful not to hit [Enter] multiple times unless you want to take multiple images
   - In the case of multiple vials, take one image of each vial separately
Processing a Prescription

Workflow Steps:

1. The Technician reviews the image on the screen ensuring its accuracy.

2. Select a function and press [C] + [Enter] to continue processing the prescription.

3. Put the product in the vial and wrap the label around the vial.
Processing a Prescription

Workflow Steps:

1. Review the dialog box on the right hand side of the screen for Bagging Activities

2. Scan vial(s)
   - In the case of multiple vials/product, scan each one at a time, NOT one multiple times

3. Scan any additional documents

4. Places each item in the prescription bag

5. Attach the label to the bag along with any other required documents
Processing a Prescription

Workflow Steps:

1. RPH verifies prescription on-screen
2. Complete Verification [Enter]
How liquids are Imaged for Verification

- Image each amber bottle standing up to show medication/water fill line
- Image each stock bottle used to fill amber bottles, including:
  - NDC
  - Drug name and strength
- Lot number & expiration date
Workflow and Recordkeeping

Workflow

• The colleague at Production can choose to bypass the new workflow if needed (in case of hardware malfunctions, or a quantity too great to image). This bypass requires the pharmacist to perform the product check manually.

• Pharmacists have the option to Reject a prescription processed through this workflow and either a) send it back to Production for re-processing or b) pull the bag and perform the product check manually.

• The primary products excluded from this workflow are: Schedule 2 (C2) products, immunizations, compounded medications and products too large/cumbersome to image (bowel prep, diapers, enemas, etc.).
  • We monitor for products that the majority of stores end up bypassing the majority of time to evaluate if products should be excluded.
  • Any product could be excluded by NDC, if needed.
  • Example of excluded product is Nitrolycerin tablets due to special packaging and lack of ability to image the tablets.

Records

• Images captured during the workflow process (and ultimately verified by the pharmacist) are stored for 2 years.

• If an image is captured and the Pharmacist chooses to verify it the ‘old way’ (see: bullet 2 above) we do not store the image. This is because we want to maintain a clear trail of what the pharmacist saw and used to verify the prescription.

• These are accessible centrally and from the Rx Image Retrieval Tool at the store.

• Virtual Verification does not change our existing credentialing process or records keeping process.
Virtual Verification declutters production and verification workspaces

**Today**

**With Virtual Verification**

**Baskets are stacked** and organized to keep prescriptions in time order while awaiting Product Verification

*Physical obstructions can make it difficult for Pharmacists to oversee workflow*

Prescriptions are bagged at Production and put into the Waiting Bin in batches, *alleviating the clutter and anxiety* that come with basket stacks
Increasing patient satisfaction
Virtual Verification simplifies the “expedite” process, resulting in an improved patient experience

Today's process, when a patient arrives to pick up Rx waiting for RPh verification

1. Patient presents at POS or Drive Thru
2. Technician expedites Rx and notifies RPh
3. Pharmacist searches baskets to find Rx
4. Scans label and vial to start QV2
5. Verifies accuracy of product manually
6. Bags Rx and moves to Green Zone
7. Notifies tech / patient that Rx is ready
8. Technician retrieves Rx from Green Zone
9. Completes sale

With Virtual Verification

1. Patient presents at POS or Drive Thru
2. Technician expedites Rx and notifies RPh
3. Pharmacist verifies accuracy of product digitally
4. Technician retrieves Rx from Waiting Bin
5. Completes sale

These steps happen simultaneously
Increasing accountability and quality
Virtual Verification workflow has been designed with patient safety and quality as the number one priority and extensively studied to make sure this enhancement meets that objective. This workflow delivers multiple benefits to quality and safety to our pharmacies, including:

**In workflow benefits:**

**Bagging Safety Scans:** In an effort to advance our quality assurance processes, additional safety scans have been added. If a technician fails to perform all safety scans during bagging, the pharmacist is required to perform manual verification.

**Image Review:** Images enable pharmacists to easily review all loose pills in Visual Verification Tray and information on each dispensed product (e.g., expiration date, lot #).

**Out of workflow benefits:**

**Patient Inquiry Resolution:** Easy to confirm quantity dispensed with a simple image retrieval tool search (e.g., 30 vs 90, 1 box vs 3 boxes).

**Potential Error Investigation Support:** Investigation supported through the image retrieval tool to confirm what was dispensed to the patient.
In Closing: There are many sources of value of Virtual Verification

<table>
<thead>
<tr>
<th>SOURCE OF VALUE</th>
<th>BENEFIT / IMPACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elevate the role of the registered pharmacist</td>
<td>• Pharmacists can be closer to patients by removing the physical handling of product it frees them up to eventually spend their time giving immunizations, counseling and performing other patient care activities</td>
</tr>
</tbody>
</table>
|                                          | • Pharmacist can focus on the product verification without interruption  
|                                          | • Improve pharmacist satisfaction and allow them to participate in a more patient centered health care model                                      |
| Increase patient satisfaction            | • Simplifies the expedite process for a more seamless patient experience  
|                                          | • Also provides a cleaner look to the pharmacy production area by removing the stacks of baskets                                               |
| Increase accountability and quality      | • Additional bagging scans that must be performed to ensure accuracy  
|                                          | • We are already working on AI capabilities that will use the captured image to detect potential errors like co-mingling and quantity discrepancies |
May 26, 2021

South Dakota Board of Pharmacy
4001 W. Valhalla Blvd., Suite 106
Sioux Falls, SD 57106

Re: Consideration of AMICUS to Perform 503B Inspections

Dear Ms. Shanard-Koenders,

On behalf of AMICUS GMP Consultants, LLC (“AMICUS”), we respectfully request consideration by the South Dakota Board of Pharmacy (“Board”) to recognize and approve AMICUS as a qualified contractor to perform inspections of 503B outsourcing facilities applying for licensure as a (resident or non-resident) Outsourcing Facility Distributor with the Board. The contractual and financial relationship for such inspections will transpire specifically between AMICUS and the license applicant. The Board will hold no contractual or financial obligation within this inspection process. This letter and accompanying documents serve to provide detailed information regarding AMICUS ownership, qualifications of inspectors, and the inspection approach utilized. AMICUS welcomes the opportunity to answer questions from the Licensing Committee and/or the Board at upcoming meetings.

My name is Becca Mitchell and I am the Director of Quality and Regulatory for AMICUS. Kristopher Le, the CEO and Principal Consultant for AMICUS, is a 2010 Doctor of Pharmacy graduate of The University of Florida College of Pharmacy. Dr. Le co-owns AMICUS, along with Jun Fabella, Russel Odegard, and Michael Pruett who are silent partners. Originally a division of Dynalabs, AMICUS is now an independently owned, private company that provides full-service consulting services in the 503B outsourcing and pharmaceutical manufacturing industries. We perform compliance audits, assist with compliance remediation, and provide validation services to FDA-registered entities across the country. The AMICUS team works with state boards of pharmacy nationwide and with FDA, including drafting and implementing Compliance Master Plans submitted to FDA for remediation of firms under consent decree. AMICUS also provides on-site auditing services of drug substance (API) manufacturers and analytical testing laboratories for clients.

All AMICUS inspections of drug product compounding or manufacturing facilities are performed by not less than two AMICUS employees, at least one of whom is a pharmacist. The three principal consultants are Dr. Kristopher
Le, Don Carter, and myself. A brief synopsis of the qualifications for each is provided below, and CVs are attached for a more thorough review.

- **Kristopher Le, PharmD; CEO & Principal Consultant** – Experienced executive with over 10 years in the pharmaceutical compounding and manufacturing industries; was the Director of 503B Operations and Pharmacist-in-Charge for Nephoton Pharmaceuticals and responsible for the first 503B inspection by FDA that yielded zero Form 483 observations. Dr. Le is currently a licensed pharmacist in nine states.

- **Don Carter, Director of Validation** – For almost 15 years, Mr. Carter has worked in engineering, validation, and formulation development with GMP-compliant firms. He has a degree in Science and Chemical Technology and brings a wealth of hands-on experience and technical expertise to the AMICUS team. Mr. Carter focuses on equipment and facility design and qualification, process validation, and drug product development strategies.

- **Becca Mitchell, PharmD; Director of Quality and Regulatory** – a 2008 graduate of the University of Arkansas for Medical Sciences College of Pharmacy, Dr. Mitchell has over a decade of experience in 503A and 503B compounding and is currently an appointed member of the Arkansas State Board of Pharmacy. During her tenure as Pharmacy Director and then VP of Quality and Regulatory for US Compounding, Inc., Dr. Mitchell hosted over 40 audits from state boards of pharmacy, FDA, DEA, and PCAB/ACHC. Dr. Mitchell is currently a licensed pharmacist in 17 states.

AMICUS employs a six-systems approach very similar to the inspection methodology outlined in FDA’s Drug Manufacturing Inspection Compliance Program. Firms are inspected for effective, compliant quality systems that include adequate description of management responsibility, appropriate resources, control of production operations, and continuous improvement evaluation. Audits are conducted on-site, generally over not less than two (2) days. The audit team tours the facility, including visual observation of material receipt & storage, sterile and non-sterile manufacturing, visual inspection, labeling, packaging, and distribution. A thorough review of the firm’s Quality Systems is performed to ensure the firm’s training program, document control, vendor oversight, batch review and disposition, product complaints, environmental monitoring, and other quality assurance functions are compliant with industry standards. Production controls including contamination control, gowning, personnel and aseptic process qualification, and equipment qualifications and calibrations are evaluated. Written policies and procedures are compared to executed documents for assessment of compliance.

At the conclusion of each inspection, the audited firm is provided with a written report of findings, including assessment of severity and references to specific industry guidance or statutory requirements. When conducted
on behalf of a client as part of due diligence, AMICUS provides a comprehensive audit report that summarizes
the company operations, details the audit observations, and assesses the overall compliance of the firm to the
stated expectations applicable to the audit. Because of its varied experience with both traditional drug
manufacturing and 503B outsourcing facilities, AMICUS is well-suited to provide effective, meaningful
inspections of drug manufacturer permit applicants that balance the necessity of compliance with preserving
patient access and prioritizing patient safety.

The following documents* are provided along with this letter for Committee consideration:

- AMICUS Ownership Disclosure*
- Consultant CVs
- Sample Audit Agenda*
- Sample Audit Report (redacted)*
- Sample Audit Checklist (Auditor Use Only, redacted)*

*These documents contain confidential & proprietary information; please do not share to the general public.

In closing, AMICUS has the experience, expertise, and availability to conduct audits that can be submitted to the
Committee for review when an applicant has not timely received an FDA inspection, to provide the Committee
with a mechanism to assess candidates for licensure or licensure renewal. It would be a sincere honor to
collaborate with the Committee and its current inspection staff in this capacity. We appreciate your consideration
of AMICUS and look forward to answering any questions Board staff, Committee members, or Board members
have during an upcoming meeting.

Respectfully,

Becca Mitchell, PharmD, FAPC
Director of Quality and Regulatory

Cc Kristopher Le, PharmD
AMICUS CEO & Principal Consultant

Enclosures
Audit Agenda

cGMP 6 Systems
PURPOSE & SCOPE

The purpose of this audit is to perform a review of the procedures, process and systems in place at the [Site Name] facility located at [Site Address] and evaluate compliance with current Good Manufacturing Practice and company internal procedures as applicable to FDA Registered 503B Outsourcing Facilities. The audit focuses on the aseptic production of sterile compounded drug products, facility and equipment controls for compounding/repackaging, release and stability testing, receipt, storage, labeling and packaging, distribution and the quality systems supporting these processes, including:

- Management Controls
- Quality Systems and Compliance
- Oversight of Laboratory Controls
- Material Management

The audit will be conducted to the standards of cGMP as per the following:

- 21 CFR Parts 11, 210, 211, and 820
- ICH Q10 Pharmaceutical Quality System
- [Site Name] Internal Policies and Procedures
# Audit Agenda - Day 1

<table>
<thead>
<tr>
<th>Item #</th>
<th>Description</th>
<th>Leader (Time)</th>
</tr>
</thead>
</table>
| 1 | Welcome and Introduction  
- Introductions  
- Review of agenda  
- Opening Presentation including Facility Layout and Organizational charts - [503B] | All (30 min) |
| 2 | Facility Tour  
- Warehouse  
- Production Areas  
- Labeling/Packaging | [Site Name] (~ 2 h) |
| | Break for lunch – may be a working lunch | 60 min |
| | Review SOPs, Policies, Guidelines, Work Instructions – Specific list of documents will be provided the morning of the audit (if an SOP Table of Contents is provided in advance); however, please include the following:  
- Master Equipment Validation Plan (Please have available)  
- Cleaning Validation (Please have available)  
- Environmental Monitoring (Please have trending and reports available)  
- Pest Control (Please have reports available)  
- Quality and Supplier Agreements (Please have available) | |
| 4 | Production Controls  
- Warehousing  
- Receiving and Sampling  
- Storage Facilities, including Document, Stability and Retain/Reserve  
- General facility control  
- Back-up generators  
- Water System(s)  
- Contamination control  
- Area/line clearance  
- Labelling controls & operations | Becca Mitchell, PharmD. |
| 5 | Validation Controls  
- Validation policy & procedure(s)  
- Qualification/validation master plan for [Site Name] facility, computer, equipment, process and cleaning  
- Cleaning Validation | Kristopher Le, PharmD. |
| 6 | Equipment & Facility Controls – Production & Lab  
- Cleaning & use logs  
- Preventive maintenance  
- Calibration and qualification  
- Cleaning verification process and calculations  
- Temperature Mapping | Becca Mitchell, PharmD. |
| 8 | Quality Release  
- QC release system including COA  
- QC data review  
- Specifications | Kristopher Le, PharmD. |
| 9 | End of Day 1 | All |
## Audit Agenda - Day 2

<table>
<thead>
<tr>
<th>Item #</th>
<th>Description</th>
<th>Leader (Time)</th>
</tr>
</thead>
</table>
| 1      | **Observation**  
- Gowning  
- Aseptic Manufacturing / Compound Process  
  - Formulation, Sterilization, Primary Packaging  
  - Environmental and Personnel Monitoring  
  **Environmental Monitoring (EM)**  
  - EM-Performance Qualification (PQ)  
  - EM Data Collection and Trending  
  - Review of EM results, sampling techniques, incubation, enumeration, training, etc.  
  - QC Release of EM Materials  | Kristopher Le, PharmD.  
(2-3 hours) |
| 2      | **Quality Systems**  
- Internal audit  
- Evaluation of compounding and laboratory changes, deviations, and trends  
- Review of equipment maintenance investigations, and related manufacturing investigations.  
- Review of process validation and associated changes  
- Equipment maintenance, calibration, and equipment performance  
- Sampling, testing, and evaluation of components (including APIs), in-process materials, for release.  | Becca Mitchell, PharmD.  
(2-3 hours) |
| 3      | **Observation**  
- Gowning  
- Aseptic Manufacturing / Compound Process  
  - Formulation, Sterilization, Primary Packaging  | Becca Mitchell, PharmD.  
(2-3 hours) |
| 4      | **Quality Systems**  
- Method validation (Identification tests; Quantitative tests for impurities’ content; Limit tests for the control of impurities)  
- OOS  
- Evaluation of specification and BUDs  
- Production records and documentation (review of data integrity)  | Kristopher Le, PharmD.  
(2-3 hours) |
| 5      | End of Day 2  | All |
## Audit Agenda - Day 3

<table>
<thead>
<tr>
<th>Item #</th>
<th>Description</th>
<th>Leader (Time)</th>
</tr>
</thead>
</table>
| 1      | **Observation**  
- Gowning  
- Compounding  
- Aseptic Packaging | Kristopher (2-3 hours) |
| 2      | **Quality Systems**  
- Internal audit  
- Evaluation of compounding and laboratory changes, deviations, and trends  
- Review of equipment maintenance investigations, and related manufacturing investigations.  
- Review of process validation and associated changes  
- Equipment maintenance, calibration and equipment performance  
  Sampling, testing, and evaluation of components (including APIs), in-process materials, for release. | Becca (2-3 hours) |
| 3      | **Observation**  
- Gowning  
- Compounding  
- Aseptic Packaging | Becca (2-3 hours) |
| 4      | **Quality Systems**  
- Method validation (Identification tests; Quantitative tests for impurities' content; Limit tests for the control of impurities)  
- OOS  
- Evaluation of specification and BUDs  
- Records and documentation (review of data integrity) | Kristopher (2-3 hours) |
| 5      | **End of Day 2** | All |
Please provide, (if not already provided) the provision of the following items to further enhance our understanding of your systems and procedures currently in place.

- Copy of the organizational chart
- List of all policies and SOPs (Table of Contents format is acceptable)
- Facility floor plan (including all areas as applicable: material receiving and storage, material preparation and cleaning areas, compounding, aseptic fill finish/packaging, visual inspection, labeling)
- Copy of your Quality Manual (if available) and Site Master File (SMF)
- Copies of any licenses (if not already included in the SMF)
- Pest Control reports
- List of audits from Health Authorities in the US, dates and any audit observations and conclusions

Have prepared the following:

- SOP binders
- Environmental monitoring reports including utilities monitoring for the previous 4 quarters
- Batch production records for product including all prior steps
- Maintenance records for process equipment used in drug product compounding
- List of deviations and OOS (including other non-product related such as not following the SOP, equipment maintenance issue, utilities or environmental monitoring alerts/action limits exceeded).
Spring Meds Inc.

Springmeds Inc. operates a website Springmeds.com that displays prices for all its products.

Patients go on to the Springmeds.com website and place their order for either a prescription medication or an OTC product. These orders are filled by one of two pharmacies. Currently Healthwarehouse in Florence, Kentucky fills most of the orders. The other pharmacy is HRX Pharmacy in Holladay, Utah. Healthwarehouse is licensed or authorized to ship to all fifty U.S. states. HRX pharmacy is only licensed in 20 states. If an order comes in for a prescription product on Springmeds.com, Healthwarehouse will contact the patient’s doctor or their pharmacy then fill and ship the order. The dispensing pharmacy will then provide Springmeds.com with a tracking number. Springmeds.com will bill the patient and send the patient their tracking number. If the patient orders an OTC product we will send some of those orders to HRX to ship out, but most will be shipped from Healthwarehouse.

We are planning on opening a pharmacy in Sioux Falls that will provide service for Springmeds.com. The website www.springmeds.com is a separate business from the Sioux Falls pharmacy. We are looking to open the pharmacy in September 2021. We would hire a pharmacist and a technician and have them work an eight hour shift, 9-5 Monday to Friday. The Sioux Falls pharmacy would manage the orders placed on the Springmeds.com website. They would confirm the order with the patient and acquire the prescription. This would be done by contacting the patient’s doctor for a new prescription or the patient’s pharmacy for a prescription transfer. Alternatively, the patient could mail in their original prescription or if appropriate we would refer them to a telemedicine provider. Once a valid prescription is received, Sioux Falls Pharmacy would defer the prescription. The dispensing pharmacy would be selected based upon if that pharmacy is licensed in the patient’s state and the level of service the pharmacy is able to provide for that order. The prescription would then be transferred to that pharmacy with detailed order instructions. The dispensing pharmacy would send notification to Springmeds.com that the order has been shipped along with the tracking number. Springmeds.com would then bill the order and send a confirmation email to the patient informing them that their order has been shipped and provide them with that tracking number.

The Sioux Falls pharmacy would over time get licensed in all states and dispense all medications from Sioux Falls for Springmeds.com.